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Liver is a critical organ for drug metabolism and is the primary site for the
expression of Phase-I drug metabolizing enzymes, which mainly catalyze the oxidation,
reduction, and hydrolysis of xenobiotics. However, in the fetus, the major function of
liver is hematopoiesis. From infants to adults, dramatic changes occur in liver functions
and the Phase-I gene expression, which can markedly affect the metabolism of drugs in
newborns and children. Characterization of the expression profiles and regulatory
mechanisms of liver development and Phase-I genes is needed for more rational drug
therapy of pediatric patients. An animal model is indispensable for studying the
mechanisms of postnatal development of Phase-I genes.
In this dissertation, we systemically characterized the model of mouse liver during
postnatal development and examined the ontogenic expression of all major Phase-I
drug metabolizing genes by RNA-sequencing. Gene ontology analysis demonstrated
that cell proliferation and immune activation pathways were active in liver at neonatal
ages and different metabolic processes were matured at different stages during
development, with the age of day 25 as the approximate time of maturation for the liver
transcriptome. Significant functional transitions in liver accompanied the ontogeny of
Phase-I genes. Four ontogenic expression patterns were identified among the 71
significantly expressed cytochrome P450s, which categorized genes into neonatal-,
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adolescent-, adolescent/adult-, and adult-enriched groups. Diverse expression patterns
were also elucidated in another 11 families of Phase-I genes, which provided a valuable
foundation for further mechanistic studies.
Long non-coding RNAs (lncRNAs) and farnesoid X receptor (FXR) mediated
regulation of gene expression were explored and addressed. The developmental
expression patterns of lncRNAs were initially characterized, which strongly suggested
the involvement of lncRNAs in the control of liver ontogeny. Comparisons of liver
transcriptome between wild-type and age-matched FXR-null mice revealed a critical role
of FXR in promoting proper liver maturation and in control of Phase-I gene expressions
during development.
In conclusion, the present dissertation has built up a valuable platform for the study
of liver developmental gene expression and regulation. Our results also provide novel
insights into identifying and further understanding the molecular targets for safe and
efficacious drug treatments in children.
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Chapter 1 : Introduction

1.1 Developmental Pharmacology
Drug treatment is aimed to obtain therapeutic effect and alleviate diseases, preferably with
minimal side effects. The rational use of drugs requires the identification of sources of variability
in drug response, quantifying the impact of the variability and modifying the drug dose to
compensate the influence. Human heterogeneity that leads to altered drug response and toxicity
profile can be physically-endowed (e.g., age, gender, genotype), physically-acquired (e.g.,
pregnancy, disease), behaviorally-linked (e.g., smoking, diet), and environmentally-induced (e.g.,
chemical exposure) (Rogers, 1994). One of the physically-endowed factors is ontogeny, which
is known as all the developmental events that occur during the existence of a living organism,
usually from the time of fertilization of the egg to the organism's mature form. Ontogeny is
closely related to studies of embryology and developmental biology, and the terms are
sometimes used interchangeably. While all the sources of variability have the potential to
influence drug response in various ways, the effect of age or ontogeny is remarkable, and will
be the focus of this thesis.
Clinical Problems
Infants and children are far different from adults in medical perspectives. Dr. Abraham
Jacobi, often referred to as the father of American Pediatrics, wrote more than 100 years ago,
“Pediatrics does not deal with miniature men and women, with reduced doses and the same
class of disease in smaller bodies, but… has its own independent range and horizon.” (Kearns
et al., 2003) In neonatal life, there are important age-dependent changes in body composition,
in weight/size and in the maturation of hepatic and renal functions. With the accumulation of
1

knowledge on normal growth and development, we are getting increasingly aware that
developmental changes significantly affect the responses to medications and an ageappropriate pharmacotherapy is needed.
However, frequently prescribed drugs for children, such as medications to treat asthma,
seizures, psychiatric disorders, gastrointestinal problems and sedatives, are largely not labeled
for pediatric use. Most of them contain pediatric disclaimers, like “no controlled studies have
been conducted in pediatric patients” or “Safety and effectiveness in children have not been
established” (Cote et al., 1996). Current practice medicine on pediatric patients is fully relied on
physician’s experience without a solid support of scientific knowledge. When physicians
prescribe a medicine to pediatric patients, in many cases, they use a reduced dose from FDA’s
guidance on adult patients. However, how much they should reduce is completely relied on their
experience. Before they make a prescription, they may not know whether patients have
appropriate enzymes in their liver to metabolize the drug, because the expression levels of drug
metabolizing enzymes in pediatric livers, particularly in neonatal livers, is unclear and what
mechanisms control the gene expression is also unknown. Lack of the basic scientific
knowledge is one of the major reasons that pediatric patients have a much greater risk to facing
challenges on adverse drug reactions than adult patients. There is an urgent need to provide
such basic knowledge to physicians. The problem of “unapproved” use of “approved” drugs in
pediatrics has left children as therapeutic orphans. The importance of generating information on
the developmental metabolic, pharmacokinetic and pharmacodynamic data needed for safe and
effective drug use in children cannot be overemphasized.
Variations in drug responses during development
Drugs undergo five stages following administration: 1) absorption into the body, e.g. from
the intestine; 2) distribution to their site of action in the body; 3) target interaction, e.g. binding to
cellular receptors or ion channels; 4) metabolic processing; 5) excretion from the body.
2

Theoretically, factors that influence any stage of the pathway can affect the overall drug
response. Variations in drug responses can be classified into two major groups. The first is
those related to the pharmacokinetic properties of drugs, such as drug metabolizing enzymes
and drug transporters, which affect how the drug is handled by the body. The second is those
influencing pharmacodynamic properties of drugs, including drug targets such as enzymes,
receptors and ion channels, and their associated pathways, which determine the drug’s effect
on the body.
Pharmacodynamics
Little information exists about the human ontogeny on the interaction between a drug and
its targets, the biochemical and physiological effect of a drug on the body, i.e., the
pharmacodynamics.

For

example,

the

apparent

developmental

differences

in

the

pharmacodynamics of morphine in neonates are directly associated with the reduced formation
of its glucuronide metabolite at early ages (de Wildt et al., 1999b). However, data on certain
drugs appear to support true age-dependent differences in pharmacodynamics. Assays in
peripheral blood monocytes cultures from subjects of different ages have demonstrated that
cyclosporine has much lower IC50 and IC90 in infants than in older subjects (Marshall and
Kearns, 1999). In addition, vitamin K-dependent proteins (protein C and prothrombin fragments
1+2) showed significantly lower plasma concentrations in prepubertal patients than in adults that
treated with warfarin and exhibited similar pharmacokinetic parameters (Takahashi et al., 2000).
Clearly, age-dependent differences in pharmacodynamics have implications and need to be
considered in pediatric pharmacotherapy.
Absorption, Distribution and Renal Elimination
When a drug is administered by non-intravenous route, the process of absorption happens
as the compound overcomes chemical, physical, mechanical and biological barriers before
being distributed in the body. The oral route is the principal route for drug administration in
3

children. The developmental differences in the physiological composition and function of the
stomach, intestine and biliary tract can alter the rate or extent of drug absorption (Allegaert et al.,
2008). Generally, the prolonged emptying and reduced intestinal motility slow down the rate of
drug absorption and potentially delay the onset of drug action in neonates and young infants
(van den Anker, 2010).
Once a drug enters the systemic circulation, it must be distributed into interstitial and
intracellular fluids. Age-dependent changes in body composition alter the physiological spaces
into which a drug will distribute. The proportion of body weight assigned to fat, protein, intra- and
extra-cellular water changes most prominently in early life (Rakhmanina and van den Anker,
2006). The volume of distribution at steady state for intravenous bolus administration of propofol
is significantly lower in neonates, compared to older children (Allegaert et al., 2007).
Although most drugs are distributed through simple passive diffusion along concentration
gradients, the expression of transporters capable of producing a biological barrier also
contributes. P-glycoprotein is an example of efflux transporters capable of limiting cellular
uptake of selected xenobiotics, which is expressed at different tissue sites (e.g., the blood-brain
barrier,

hepatocytes,

enterocytes

and

tumors).

Studies

in

animals

demonstrated

developmentally regulated P-glycoprotein expression which may affect drug distribution
(Mahmood et al., 2001; Rosati et al., 2003), but this has not been systematically studied in
humans.
For drugs that undergo extensive renal elimination, it is necessary to take into consideration
the developmental changes in renal function when selecting an age-appropriate dose regimen.
Both the glomerular filtration rate and tubular secretion increases rapidly during the first two
weeks of life and then rises steadily until adult values are reached at 6 to 12 months of age
(Kearns et al., 2003). Treatment of preterm neonates with gentamicin may need to increase the
dosage interval from 12 hours to 18 hours to prevent accumulation of drugs to potentially toxic
4

serum concentrations (Mulhall et al., 1983). Prenatal exposure to certain medications, such as
betamethasone and indomethacin, may alter the normal pattern of renal maturation in neonates
(van den Anker et al., 1994). Thus for drugs primarily eliminated by kidney, treatment regimens
need to reflect both development and treatment-associated maturational changes in kidney
function.
Drug Metabolism
Drug metabolism is the process of biotransformation, generally converting lipophilic
chemicals, which are readily absorbed from gastrointestinal tract and other sites, into hydrophilic
chemicals, which are readily excreted in urine or bile. While, in most cases, metabolism reduces
the ability of a drug to produce a pharmacological action, it can also generate metabolites that
have more significant pharmacological or toxic effect, for instance, in the case of prodrugs.
Metabolism is the most critical step in ADME process of a drug, because it is the only step that
alters the chemical property of the drug.
The biotransformation is catalyzed by various drug metabolizing enzymes which are mainly
expressed in the liver. The functional maturation of liver during postnatal development affects
the expression of drug metabolizing enzymes, and profound changes of drug metabolizing
enzyme activities during development impact drug efficacy and the risk of adverse events in
neonates and young children. Numerous children treated with the antibiotic chloramphenicol
suffered from “gray baby syndrome”. The symptoms include vomiting, grey color of the skin and
cardiovascular collapse. This is due to the immature level of UDP glucuronosyltransferse in
infants to metabolize the drug, resulting in the drug or metabolites accumulation to toxic levels.
The use of benzyl alcohol as a preservative in intravenous fluids has caused gasping syndrome
or even death in newborns, especially premature infants. And this is because of the immature
level of glycine N-acetyltransferase in infants (Hines, 2013). The drug cisapride used to control
gastric reflux in neonates can lead to drug-induced long QT syndrome. Cisapride is mainly
5

metabolized and inactivated by CYP3A4. The low activity of CYP3A4 during the perinatal period
results in toxic levels of the drug, which was later withdrawn from the market. These examples
of tragic adverse events signal the importance of research on developmental expression of drug
metabolizing enzymes.
A recent review has summarized the patterns of human drug metabolizing enzyme
ontogeny into three classes based on both in vitro studies using human liver tissue banks and in
vivo studies in pediatric patients undergoing drug therapy (Hines, 2013). Class 1 enzymes are
highly expressed in the fetus and within a few days to as long as two years after birth, their
expression is either silenced or reduced to very low levels, examples of which are FMO1 and
CYP3A7. Enzymes belonging to the second class are expressed at relatively constant levels
throughout development, and the level may or may not increase modestly within the first year
after birth. CYP2B6, CYP2C19 and SULT1A1 all exhibit this developmental pattern. Class 3
enzymes are the largest group. They are expressed at low levels in the fetus, and significant
increases in expression to mature levels occur within a few weeks to one or two years after birth.
In this group, CYP2D6 is an example of early maturation (a few weeks after birth), and CYP3A4
matures a few years after birth, whereas FMO3 and CYP2C9 adult expressions are not
observed until post-puberty. The evaluation and classification of drug metabolizing enzymes into
three ontogeny classes may be utilized to suggest enzyme functions and regulation. The
enzymes within the same class may share functional significance in specific time windows
during development. Some common regulatory mechanisms are also likely among enzymes
belonging to the same class.
Examples of pharmacokinetic studies provide insight into the ontogeny of drug metabolism
by specific Phase-I enzymes. The plasma clearance of intravenously administered midazolam is
primarily a function of hepatic CYP3A4 and CYP3A5 activity, and the activity level increases
from 1.2 to 9 ml/min/kg during the first three months of life (de Wildt et al., 1999a). The
6

clearance of carbamazepine from plasma, which depends largely on CYP3A4, is greater in
children (aged 3-10 years) than in adults (Riva et al., 1985), which requires higher weightadjusted doses of the drug to achieve therapeutic levels. The apparent half-life of phenytoin,
primarily metabolized by CYP2C9, is prolonged to approximately 75 hours in preterm infants,
but decreases to about 20 hours in term infants and to approximately 8 hours after the second
week of life (Loughnan et al., 1977). Furthermore, the CYP1A2 catalyzed caffeine demethylation
in adolescent girls appears to decline to levels as in adults when girls reach Tanner stage 2,
whereas this occurs at Tanner stage 4 or 5 in adolescent boys, thus demonstrating a genderbased difference in CYP1A2 ontogeny (Kearns et al., 2003).
Phase-II drug metabolizing enzymes are involved in synthetic reactions including
glucuronidation, sulfation, methylation or acetylation. These conjugation pathways seem to
display much less isoform-specific ontogeny in early life than Phase-I enzymes (Allegaert et al.,
2008). Glucuronidation is of critical roles in drug clearance, as it dramatically increases the
water solubility of drugs for subsequent elimination through urine or feces. The metabolite of
tramadol undergoes glucuronidation, and the ratio of glucuronidated tramadol metabolite to total
tramadol metabolite was significantly lower in early compared to late neonatal life in a study
conducted by Allegaert et al. (22% versus 33% respectively, p<0.0001). Similar lower
conjugation level for paracetamol in urine samples of neonates was also observed by these
researchers. It is also worth mentioning that drug metabolizing enzymes with substantial extrahepatic expression (e.g., CYP3A4, CYP3A5, and isoforms of UGT) may alter the predicted
pharmacokinetics based on the liver expression levels.
Previous studies have identified windows of hyper-variability during human drug
metabolizing enzyme ontogeny (Hines, 2013). Constitutional, environmental, genetic factors,
age and comorbidity can all have an impact on drug response during development. It is
therefore critical to understand not only the ontogeny but also the regulatory mechanisms of
7

developmental changes in order to provide individualized drug therapy in pediatrics that is safe
and effective. Hence, this thesis utilizes mouse as a model to study liver ontogeny and tries to
elucidate the critical factors involved in developmental regulation, with a focus on Phase-I drug
metabolizing enzymes.

1.2 The Study of Phase-I Drug Metabolizing Enzymes
Drug-metabolizing enzymes play a central role in the elimination of drugs in the body
(Nishimura and Naito, 2006). The metabolic reactions of hydrolysis, reduction, and oxidation
usually expose or introduce a functional group to a drug that may be further converted to a
water-soluble conjugate. The reactions of hydrolysis, reduction, and oxidation are often called
Phase-I reactions, and the conjugation reactions are often referred to as Phase-II reactions. The
enzymes involved in hydrolysis, reduction, and oxidation of drugs are classified as Phase-I
metabolizing enzymes (Parkinson and Ogilvie, 2008). The major Phase-I enzymes to be studied
in this thesis include hydrolysis enzymes of carboxylesterases (CES), Paraoxonases (PON),
and epoxide hydrolases (EPHX); reduction enzymes of aldo-keto reductases (AKR), quinone
oxidoreductase (NQO), and dihydropyrimidine dehydrogenase (DPYD); and oxidation enzymes
of alcohol dehydrogenases (ADH), aldehyde dehydrogenases (ALDH), aldehyde oxidases
(AOX), flavin monooxygenases (FMO), cytochrome P450s (P450), NADPH-cytochrome P450
oxidoreductase (POR), and xanthine oxidoreductase (XDH).
Animal Model
Multiple factors contribute to the lack of appropriate pediatric studies. Children have a
relatively small market share, and adequate research funding from government, industry, and
health care providers is often lacking. There may be potential long-term adverse effects in
pediatric clinical trials, which can lead to fear of legal liability. Also, parents are usually reluctant
8

to allow their children to be research subjects. These ethical, financial and logistical
considerations limit the clinical drug studies in children. On the other hand, pursuing studies of
drug safety and efficacy in developing animals has several theoretical advantages. Animal
developmental study may point out age-specific risks or toxicities not apparent from adult animal
or human studies, and help guide initial dosing range for pediatric clinical trials. The shorter life
spans and generation time of laboratory animals allow more rapid detection of potential longterm consequences of early life drug exposure. More importantly, they permit the study of
mechanisms by invasive physiologic, histologic and biochemical measurements that are not
achievable in human studies in infants and children. Powerful genetic tools have been
developed in animal models, like mice, which help examine the effects of specific genes on the
resulting phenotype (Berde and Cairns, 2000).
We will use an animal model, mouse instead of human samples to study the developmental
regulation of Phase-I genes in this thesis. Several limitations exist in studies of the
developmental regulation of drug metabolizing enzymes with human samples. The first limitation
is the ethical and technical issues in recruiting human subjects and obtaining suitable human
samples of different ages during development. Secondly, variations in human metabolic
capacity, which may be caused by genetic or environmental factors, can interfere with studies
aimed to reveal the regulatory mechanisms that are only due to age. Furthermore, mechanistic
loss-of-function or gain-of-function strategies are not applicable directly in human samples.
Animal models are advantageous in overcoming these limitations.
While not all mouse Phase-I genes have been shown to metabolize specific substrate,
more than half of the P450 isoforms exhibit sequence homology to human isoforms (Moscovitz
and Aleksunes, 2013). Several laboratories, including us, have examined the expression of
some Phase-I genes at early ages in mouse or rat liver, including P450s (Hart et al., 2009; Cui
et al., 2012c), Ces (Zhu et al., 2009), Akr (Pratt-Hyatt et al., 2013), Adh and Aldh (Smolen et al.,
9

1990; Alnouti and Klaassen, 2008), Pon (Li et al., 1997), and Fmo (Falls et al., 1995;
Cherrington et al., 1998; Janmohamed et al., 2004). Developmental expression patterns of
some examined Phase-I genes in mice and rats are similar to those in humans.
The enzyme activities in animal models might not be exactly the same as those in humans,
but the molecular events in regulating these developmental changes can be quite indicative as
the mechanisms of basic biology are highly conserved among species, and the molecular
mechanisms are what we focus on. For example, in the event of nuclear receptors regulating
P450 gene expression, it is generally considered that AhR is responsible for the mRNA
induction of family 1, CAR for family 2, PXR for family 3, and PPARα for the mRNA induction of
family 4 of P450s, and this principle is consistent between human and mouse, indicating strong
homology in regulatory mechanism of gene expression.
Novel technology: RNA-Sequencing
Previous studies quantified Phase-I gene expression on the mRNA level by either Northern
blot, RT-PCR, microarrays, or multiplex suspension bead arrays (Hart et al., 2009; Li et al.,
2009a), which only provide relative quantification of a given gene. These technologies detect
mRNA levels by probe hybridization and fluorescence signal intensity, which cannot compare
expression levels among various Phase-I genes, because different probes may have different
hybridization efficiency. With the development of next-generation sequencing technologies,
such as RNA sequencing (RNA-Seq), it is possible to define a whole transcriptome with low
background noise, no upper limit for quantification, and a high degree of reproducibility for both
technical and biological replicates (Mortazavi et al., 2008; Nagalakshmi et al., 2008). More
importantly, RNA-Seq quantifies the true abundance of mRNA molecules in biological samples
and enables comparison of the expression of all genes (Malone and Oliver, 2011). Furthermore,
RNA-Seq has the power to quantify expression levels of alternative transcripts of the same gene
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and to identify novel transcripts efficiently (Pan et al., 2008; Wang et al., 2008; Malone and
Oliver, 2011).
In this thesis, taking advantage of the powerful RNA-Seq technique, we will discuss the
whole liver developmental transcriptome in Chapter 2, which is the physiological base for the
maturation of Phase-I drug metabolizing enzymes. In Chapter 3, we will examine and compare
all of the P450 isoforms and their alternative transcripts during liver development, which is the
most important family of Phase-I genes. In Chapter 4, we will investigate the ontogeny of
several other major families of Phase-I genes involved in hydrolysis, reduction, and oxidation of
xenobiotics in liver. In Chapter 5, we will take a further step to explore the regulation of Phase-I
genes during liver maturation.

1.3 Developmental Regulation and Farnesoid X Receptor
Gene expression is the process by which information from a gene is used in the synthesis
of a functional gene product, involving steps of transcription, RNA processing, translation, etc. In
most case, the product of a gene is a protein with structural or catalytic functions, whereas nonprotein coding genes can generate functional RNAs, such as ribosomal RNA (rRNA), micro
RNA (miRNA), and long non-coding RNA (lncRNA).
The genetic information is stored in the DNA sequence of a gene, which is wrapped around
histone proteins to form the higher order structure of DNA, the nucleosome and chromosome.
The transcription of DNA to RNA is initiated by the transcription machinery containing a group of
transcription factors and the RNA polymerase. Nuclear receptors, as an important class of
transcription factors, can sense molecular signals in the cell and directly bind to DNA to regulate
gene expression. The non-sequence changes in DNA structure, also known as epigenetics, can
influence transcription. For example, the DNA methylation at CpG islands and post-translational
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modifications to histones may alter the chromatin conformation and interact with transcription
machinery to regulate transcriptional activity.
The transcription produces a primary RNA transcript that is complementary to the DNA
sequence. The primary mRNA has to undergo a series of modifications to become a mature
mRNA. These include 5’ capping, which adds a 7-methylguanosine to the 5’ end of the
transcript and have the function to protect the RNA from degradation and aid in the mRNA
transport to cytoplasm. Another modification is 3’ cleavage and polyadenylation. When the RNA
is transcribed close to the end, there is usually a polyadenylation signal in the sequence, which
initiates the binding of polyadenylation factors and allows cleavage at the 3’ end of the transcript
and addition of a poly-A tail containing ~200 adenines. The tail also protects the RNA from
degradation and may interact with other proteins to facilitate mRNA export and translation. A
very important modification of the eukaryotic pre-mRNA is splicing, which removes intron
sequences and keeps the coding exons connected together for translation. In certain cases,
some intron sequences can be retained or exons removed in the mature mRNA, a process
called alternative splicing that creates different transcripts from a single gene. Occasionally, a
process call RNA editing occurs that can make discrete changes to specific nucleotide
sequences within an RNA, including insertion, deletion, or nucleotide base substitution. The
processing of lncRNAs is generally the same as mRNA, while the processing of small ncRNAs
can be quite different. For examples, miRNAs are first transcribed with a cap and poly-A tail,
and then cleaved by Drosha in the nucleus and Dicer in the cytoplasm to generate mature
miRNAs.
Mature mRNAs must be transported from the nucleus to the cytoplasm where they bind to
ribosomes and are translated into amino acid sequences. The polypeptides may then undergo
conformational changes and translocations, becoming the functional molecules at their targeted
site. Post-translational modifications, such as phosphorylation and ubiquitination, may either
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increase the activity of a protein or mark the protein for degradation. A schematic summary of
the gene expression and regulation process is illustrated in Fig. 1.1.
Regulation of Phase-I gene expression
The changes in Phase-I gene expression and enzyme activity can affect individual
responses to drugs, both in terms of therapeutic effect as well as adverse reactions. Regulation
of Phase-I gene activity can happen at each step of the gene expression process. Among these
steps, transcription is a critical determinant of the gene expression level. Studies have shown
the strong correlation between mRNA expression and enzyme activity for most cytochrome
P450s in human liver (Rodriguez-Antona et al., 2001). Numerous mechanisms have evolved for
regulating transcription. At DNA level, these include promoters, enhancers, silencers and
insulators. Various protein factors interact with these DNA elements to modulate transcription
rates, such as general transcription factors, activators, repressors, and chromatin remodeling
complex. From fetus to adult, the inherited genomic DNA sequence in cells of an individual is
normally the same. So the changes of drug metabolizing gene expression during postnatal liver
development are largely regulated by epigenetic factors. And here in this thesis, we will
characterize the expression of lncRNAs in mouse liver, in order to identify their regulatory roles
during development. We will also focus on a critical hepatic nuclear receptor, farnesoid X
receptor, in regulating the ontogeny of liver and Phase-I gene expression.
Long non-coding RNAs
LncRNAs have important regulatory roles in multiple steps of gene expression. Due to the
ability of lncRNA to interact with both DNA and proteins, it can serve as a guide to promote
interactions between targeted DNA sequence and transcription factors or chromatin modulators,
a process that regulates gene expression. For example, the lncRNA HOTAIR functions to guide
the Polycomb Repressive Complex 2 to the HOXD gene locus, resulting in HOXD gene
silencing during embryonic development (Rinn et al., 2007). LncRNA can also target miRNAs in
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post-transcriptional regulation. The linc-MD1 lncRNA functions as a competing endogenous
RNA to repress miR-133 and miR-135 activity and aid in muscle differentiation (Cesana et al.,
2011). Considering the pervasive expression and diverse function of lncRNAs, it may also play
a role in regulating the expression of Phase-I metabolizing enzymes. However, few studies have
explored the involvement of lncRNAs in regulation of drug metabolizing genes.
Farnesoid X Receptor
Nuclear receptors are a class of cellular proteins that are responsible for sensing various
hormonal or molecular signals. In response, these receptors work together with other proteins to
regulate the expression of specific genes, thereby controlling the development, homeostasis,
and metabolism of the organism. FXR is one member of the nuclear receptor superfamily with
the gene symbol NR1H4. It was first cloned from rat liver in 1995, and considered as an “orphan”
nuclear receptor because the natural ligands for FXR were unknown at that time, although it
could be activated by high concentrations of farnesol (Forman et al., 1995). Bile acids were later
identified as the endogenous ligand of FXR in 1999 (Wang et al., 1999).The FXR protein shares
the common structure with other nuclear receptors, including the DNA-binding domain in the Nterminal region and the ligand-binding domain in the C-terminal region. Like many other nonsteroid hormone nuclear receptors, FXR binds to specific DNA response elements as a
heterodimeric complex with the retinoid X receptor. The most recognized FXR response
element is an inverted repeat separated by one nucleotide (IR1), detected in many FXR target
genes (Zhu et al., 2011).
The metabolism of cholesterol to bile acids and their subsequent excretion in the feces is
the primary pathway for the body to eliminate cholesterol. As bile acids travel down the small
intestine, ~95% are reabsorbed and transported back to the liver via the enterohepatic
circulation. Since approximately 5% of bile acids are eliminated in each cycle, the liver must
synthesize an equivalent amount to maintain a constant bile acid pool. Bile acids are
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physiologically important because of their detergent-like properties that facilitate lipid absorption.
However, these same properties also make bile acids highly cytotoxic when their blood or
cellular levels increase. As a sensor of bile acid levels, FXR has an important role in maintaining
bile acid homeostasis, regulating all aspects of bile acid metabolism. Cholesterol 7αhydroxylase, also known as CYP7A1, is the rate-limiting enzyme in the classic pathway of bile
acid synthesis. Activation of FXR by increased bile acids level induces one of its target genes,
the small heterodimer partner (SHP), which can dimerize and inactivate the transcription factors
that upregulate CYP7A1 expression, resulting in a decrease in CYP7A1 expression and bile
acid synthesis (Goodwin et al., 2000). FXR also regulates genes involved in 1) bile acid
secretion from hepatocytes to bile canaliculi, e.g., BSEP and MRP2; 2) bile acid uptake from the
intestine or from the blood into the hepatocytes, e.g., ASBT, IBABP, and NTCP; 3) bile acid
conjugation and detoxification, e.g., SULT2A1, UGT2B4, and BACS (Lee et al., 2006).
Patients on bile acid supplementation were found to display low high-density lipoprotein
(HDL) cholesterol levels (Leiss and von Bergmann, 1982), and mouse model with FXR knockout
was distinguished from wild-type by elevated serum and hepatic cholesterol and triglycerides,
and a pro-atherogenic serum lipoprotein profile (Sinal et al., 2000). These suggested a role of
FXR in control of lipid metabolism and further studies identified several FXR targeted genes in
this process. Apolipoprotein (apo) A-I is the major protein component of HDL in plasma, the
expression of which can be suppressed by FXR activation through either direct binding or
induction of SHP (Claudel et al., 2005). FXR also induces the expression of the phospholipid
transfer protein, an enzyme involved in HDL remodeling, and thereby modulates HDL levels.
ApoC-II is an activator of lipoprotein lipase, a key enzyme in the clearance of serum triglyceride.
And FXR has been found to bind and induce the expression of apoC-II, thus facilitating
triglyceride metabolism (Kast et al., 2001).
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More and more data have also suggested a link between FXR and glucose homeostasis.
Initially in type II diabetic patients, treatment with bile acid sequestrants were shown to lower
plasma glucose level. In primary rat hepatocytes, D-glucose increased FXR mRNA in a doseand time-dependent manner, whereas in animal models of diabetes, FXR expression was
decreased (Duran-Sandoval et al., 2004). In addition, activation of FXR in mice results not only
in hypoglycemia, but also in altered hepatic expression of phosphoenolpyruvate carboxykinase,
which catalyzes the initial step of gluconeogenesis, and glucose-6-phosphatase, which
catalyzes the last committed step of this process (Zhang et al., 2006).
In addition to the identified roles of FXR as a key metabolic regulator, it has been found to
be important for liver regeneration. FXR promotes liver repair after injury, and activation of FXR
is able to alleviate age-related defective liver regeneration, probably through activating Foxm1b
expression, which is required for the timely expression of many cell cycle regulators during
regeneration (Chen et al., 2011). Hepatocyte-specific deletion of FXR delays liver regeneration
in mice, which is associated with delayed cyclin D1 activation (Borude et al., 2012).
Furthermore, studies using chromatin immunoprecipitation coupled with sequencing (ChIPSeq) have characterized the genome-wide FXR binding sites, which were detected near
previously unknown target genes with novel functions, including diverse cellular signaling
pathways, apoptosis, autophagy, hypoxia, inflammation, RNA processing, metabolism of amino
acids, and transcriptional regulators (Lee et al., 2012). However, the role of FXR in liver
maturation and developmental regulation of Phase-I genes has not been explored. In the
immediate neonatal period, bile acids are required for the newborns to absorb milk. There is a
surge of serum and liver bile acids levels after birth (Cui et al., 2012a), so the increased
activation of FXR immediately after birth may play a role in regulating neonatal gene expression.
Most of the known liver functions regulated by FXR are established during postnatal liver
development, such as bile acid circulation and lipid metabolism, and disorders like fatty liver
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may have roots in the neonatal period(Beath, 2003). So understanding the role of FXR in liver
maturation may provide important insights on liver physiology and diseases. Hence, this thesis
will utilize FXR knockout mouse model to study the involvement of FXR in regulation of liver
maturation and Phase-I gene ontogeny.
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Fig. 1.1
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Fig. 1.1 Illustration of Gene Expression and Regulation.
Commonly in mammalian cells, the genetic information is encoded in DNA and flows to RNA
and protein. DNA sequences are essential in determining the gene activity. At transcriptional
level, epigenetic signatures, such as DNA methylation and histone modifications, can alter the
chromatin conformation or interact with nuclear receptors (NR) and other transcription factors
(TF) to influence the activity of RNA synthesis. The transcribed pre-mRNA undergoes RNA
processing to generate mature messenger RNA, which is transported out of the nucleus and
translated into protein. Post-transcriptionally, the steps of RNA processing, translation and the
stability of RNA and protein are all under tight control and can affect the gene activity through
regulation. One group of RNA is not translated into protein and designated as non-coding RNA
(ncRNA), which plays important roles in modulating gene expression at multiple steps, e.g.,
through interaction with transcription or RNA degradation machinery.
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Chapter 2 : Developmental Programming of Protein-coding and Long
Non-coding RNAs in Mouse Liver

2.1 Abstract
The liver is a vital organ with critical functions in metabolism, protein synthesis and immune
defense. Most of the liver functions are not mature at birth and many changes happen during
postnatal liver development, which may underlie the ontogenic expression of Phase-I drug
metabolizing genes and lead to differential vulnerabilities at different developmental stages.
However, the details of what changes occur in liver after birth, at what developmental stages
they occur, and the regulation of the developmental process are not clearly known. Long noncoding RNAs have been known to be involved in organ development and cell differentiation.
Here, we analyzed the transcriptome of mouse liver from perinatal to adult ages by RNASequencing, with an attempt to understand the role of lncRNAs in liver maturation. We found
around 15,000 genes expressed, including about 2,000 lncRNAs. Most lncRNAs were
expressed at a lower level than protein coding RNAs. Both protein-coding genes and long noncoding RNAs displayed three major ontogenic patterns: enriched expression at neonatal,
adolescent, or adult stages. Neighboring protein coding and non-coding RNAs showed the trend
to exhibit highly correlated ontogenic expression patterns. Gene ontology (GO) analysis of overexpressed genes during development revealed that cell proliferation and immune activation
related processes were enriched at neonatal ages, tissue organization pathways were enriched
at adolescent ages and livers at day 25 matured close to adult levels. GO analysis of underexpressed genes showed the immunity in liver was immature at neonatal ages and different
metabolic processes matured at different stages during development. These data revealed
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significant functional transition during postnatal liver development and indicate the potential
importance of lncRNAs in liver maturation.

2.2 Introduction
The liver is the largest internal organ in the body, taking up about 2-4% of body weight in
humans. It is also a vital blood reservoir by virtue of its large vascular capacity, which contains
10 to 15 percent of total blood volume. There are mainly five types of cells in liver. The
hepatocytes are the parenchymal cells of the liver, and their prominent Golgi system and rough
endoplasmic reticulum enable them to synthesize and secrete a variety of proteins. The
hepatocytes also initiate the formation and secretion of bile. The endothelial cells lining the
sinusoids serve as a barrier between the blood and hepatocytes. The cholangiocytes are the
epithelial cells of the bile duct, and contribute to bile secretion through release of bicarbonate
and water. Two other cell types line the sinusoids: the Kupffer cells, which are resident
macrophages, and the stellate cells, which store fat and vitamin A.
As part of the digestive system, a matured liver plays a major role in nutrient homeostasis,
including the synthesis, metabolism and transport of carbohydrates, proteins and fats. Venous
blood from the stomach and intestine flows through the liver by the portal vein before entering
systemic circulation. Thus liver is the first organ to encounter and deal with ingested drugs,
environmental toxicants and intestinal bacteria. Bioactivation, detoxification and filtration of
particulates in immune defense are also critical functions of the liver (Jaeschke, 2008). Whereas
in utero, fetal liver is the major hematopoietic organ, generating blood cells, and hematopoiesis
is active in liver even shortly after birth (Takeuchi and Miyajima, 2006). Definitive hematopoiesis
requires a specific microenvironment in the organ. Therefore, from birth to maturity, there are
dramatic changes happen in liver to achieve the organ growth and functional transition. And the
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differences between neonatal and adult livers have been implicated in clinical issues. Disorders
of iron metabolism such as hemochromatosis having severe effects in neonates including
fulminant liver failure may be due to the active hematopoiesis in neonatal liver (Beath, 2003).
Age-related sensitivity to drugs is at least partly attributable to differences in hepatic metabolic
activity (Pineiro-Carrero and Pineiro, 2004).
Mouse liver originates from the gut endoderm on embryonic day 8.5, and epigenetic
markings, such as unwinding of the chromatin by FoxA transcription factors, contribute to the
competence of embryonic liver development (Zaret, 2002). Signals such as FGF-1, FGF-2 and
BMP4 from the cardiac mesoderm specify the foregut endoderm to begin expressing liverspecific genes. One day later, cells forming the hepatic endoderm assume a columnar
morphology and are ready to form the liver bud. Expression of homeobox and prospero-related
homeobox 1 genes are essential to the formation of liver bud. By embryonic day 15,
hepatoblasts begin to differentiate into hepatocytes and bile-duct epithelial cells. HNF-6, HNF1β and the Notch/Jagged signaling pathway induce differentiation toward a biliary epithelial
lineage, while HNF-4α followed by C/EBPα produces mature hepatocytes (Nejak-Bowen and
Monga, 2008; Si-Tayeb et al., 2010). The differentiation process is also driven by the secretion
of oncostatin M by blood cells in fetal liver (Kamiya et al., 1999). Although extensive researches
have been done and advanced knowledge has accumulated on embryonic liver development,
many aspects remain unknown in the postnatal liver development, such as the timeline of liver
functional switch, the factors regulating liver growth and the mechanisms driving the organ
maturation.
Many previous studies have focused on examination of protein coding genes during liver
development without a special attention on long non-coding RNAs (lncRNAs). lncRNAs are
non-protein-coding RNA transcripts longer than 200 nucleotides (Kapranov et al., 2007). They
are alternatively spliced, contain 5’-capping and 3’-polyadenylation just like protein-coding RNAs,
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but have few or no open reading frames (Cabili et al., 2011a).

They either locate in the

intergenic regions, called long intergenic noncoding RNAs (lincRNAs), or partially overlap with
protein coding genes and can be transcribed from sense or antisense strand of the gene (Pauli
et al., 2012). Comparative analysis has indicated that lncRNAs are evolutionarily conserved,
especially at the promoter region (Guttman et al., 2009). The expression level of lncRNAs are
usually lower than protein coding RNAs (Cabili et al., 2011b; Pauli et al., 2012), and they are
expressed in tissue-specific and developmentally regulated manners (Amaral et al., 2008; Cabili
et al., 2011b; Pauli et al., 2012). Some specific lncRNAs are transcriptionally regulated by key
transcription factors in a mechanism similar to their neighborhood protein coding genes
(Guttman et al., 2009). lncRNAs have been demonstrated to serve as signal, decoy, guide or
scaffold to regulate various biological processes (Wang and Chang, 2011), including the cell
cycle (Hung et al., 2011), pluripotency, X-inactivation (Ogawa et al., 2008), cell differentiation
(Pauli et al., 2012), and organ development and maturation (Cesana et al., 2011; Hu et al., 2011;
Alvarez-Dominguez et al., 2014).

LncRNAs have also been associated to liver disease

progress (Spizzo et al., 2012; Shi et al., 2013; Li et al., 2014). Yet whether long non-coding
RNAs are involved in regulation of postnatal liver development has not been explored before.
In the current study, we used RNA-Sequencing (RNA-Seq) to quantify the liver
transcriptome during the developmental period from perinatal stage to adult. RNA-Seq allows
the analysis of the whole transcriptome with lower background noise, higher sensitivity, and a
high degree of reproducibility compared to traditional technologies (Mortazavi et al., 2008;
Nagalakshmi et al., 2008). More importantly, RNA-Seq quantifies the true abundance of RNA
molecules in biological samples and enables the comparison of expression of all genes in
multiple samples (Malone and Oliver, 2011). It also provides the chance for us to investigate the
expression of long non-coding RNAs during liver maturation. Our results revealed the dynamic
transcriptional changes happened in liver during postnatal development with specific transition
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and maturation ages defined, and also suggested the potential importance of lncRNAs in liver
maturation, which may facilitate future investigations to identify mechanistic roles of lncRNAs in
regulation of gene expression during liver maturation.

2.3 Materials and Methods
Animals
Eight-week-old C57BL/6 breeding pairs of mice were purchased from The Jackson
Laboratory (Bar Harbor, ME). Mice were housed according to the American Animal Association
Laboratory Animal Care guidelines and were bred under standard conditions in the Laboratory
Animal Resources Facility at the University of Kansas Medical Center. The use of these mice
was approved by the Institute of Laboratory Animal Resources. Breeding pairs were established
at 4:00 p.m. and separated at 8:00 a.m. the following day. The body weights of the females
were recorded each day to determine pregnancy status. Livers (n = 3) from male offspring were
collected at the following 12 ages: day -2 (gestational day 17), day 0 (right after birth and before
the start of suckling), day 1 (exactly 24 hours after birth), and day 3, 5, 10, 15, 20, 30, 45, and
60 (collected around 9:00 a.m.), which represents periods of prenatal (day -2), neonatal (day 0
to 10), juvenile (day 15 to 30), and young adult (day 45 and 60). Due to potential variations
caused by the estrous cycle in maturing adult female mice, only male livers were used for this
study. Livers were immediately frozen in liquid nitrogen after removal and stored at -80°C.
Total RNA Extraction
Total RNA was isolated by using RNAzol B reagent (Tel-Test Inc., Friendswood, TX)
according to the manufacturer’s protocol. RNA concentrations were quantified using a
NanoDrop Spectrophotometer (NanoDrop Technologies, Wilmington, DE) at a wavelength of
260 nm. The integrity of the total RNA was evaluated on an Agilent 2100 Bioanalyzer (Agilent
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Technologies Inc., Santa Clara, CA) and the samples with RNA integrity values larger than 7.0
were accepted for sequencing library construction.
cDNA Library Construction
The cDNA libraries from all samples were prepared by using an Illumina TruSeq RNA
sample prep kit (Illumina, San Diego, CA). Three micrograms of total RNA were used as the
RNA input based on the manufacturer’s recommendation. mRNAs were isolated from the total
RNAs by poly-A selection using poly-T primers. RNA fragmentation, first and second strand
cDNA syntheses, end repair, adaptor ligation, and PCR amplification were performed according
to the manufacturer’s protocol. Fragments of the cDNA library ranged from 220 to 500 bps with
an average size at 280 bp (including 120 bp adapter sequences). Quality of the cDNA libraries
was evaluated using an Agilent 2100 Bioanalyzer (Agilent Technologies Inc., Santa Clara, CA)
before sequencing.
RNA-Seq
RNA-Seq was performed on an Illumina HiSeq 2000 instrument by the Genome
Sequencing Facility at the University of Kansas Medical Center. Clusters of the cDNA libraries
were generated on a TruSeq flow cell and sequenced for 100 bp paired end reads (2 × 100)
with a TruSeq 200 cycle SBS kit (Illumina, San Diego, CA). A PhiX bacteriophage genome and
a universal human reference RNA were used as controls and sequenced in parallel with other
samples to ensure that the data generated for each run were accurately calibrated during the
image analysis and data analysis. In addition, the PhiX was spiked into each cDNA sample at
approximately 1% as an internal quality control.
RNA-Seq Data Analysis
After the sequencing images were generated by the sequencing platform, the pixel-level
raw data collection, image analysis, and base calling were performed by Illumina’s Real Time
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Analysis software. The output bcl files were converted to qseq files by Illumina’s BCL Converter
1.7 software and subsequently converted to FASTQ files for downstream analysis. For the
analysis of protein-coding and non-coding genes at all 12 ages, FASTQ files were aligned with
Tophat 1.4.1. Custom GTF was supplied to the program, which was compiled from Ensembl 66
genes and selected (non-overlapping) Noncode v3.0 models (Bu et al., 2012). Cufflinks 1.3.0
(Trapnell et al., 2010) was used to quantitate expression levels with the same custom GTF file
provided. The RNA abundance was expressed as the number of fragments per kilobase of exon
per million reads mapped (FPKM). For the analysis of samples at the 6 representative ages of
day -2, 1, 5, 20, 25 and 60, the RNA-Seq reads from the FASTQ files were mapped to the
mouse reference genome (GRCm38/mm10) by Tophat 2.0.8. The output files in BAM format
were analyzed by Cufflinks 2.1.1 to estimate the transcript abundance.
Gene Ontology Analysis
Statistically significant differential expression in this analysis were defined using the
following criteria 1) the gene mean FPKM>1 across the ages; 2) fold change for the average
FPKM of the three replicates >1.5 between compared samples; 3) Benjamini-Hochberg
adjusted p-values from t-test <0.05. Lists of differentially expressed genes at ages of day -2, 1,
5, 20 and 25 compared to day 60 in mice were supplied to High-Throughput GoMiner for
biological interpretation (Zeeberg et al., 2005). Significantly enriched GO categories were
selected with a false discovery rate (FDR) <0.05.
Data Visualization and Statistics
For the visualization of developmental gene expression patterns in liver, protein-coding and
non-coding genes were separated and hierarchically clustered (Pearson correlation distance,
average linkage). ANOVA was used to test for significant difference in expression during
development. P-values were adjusted using Benjamini-Hochberg algorithm with a threshold of
0.05. Protein-coding genes were from Ensembl 66, and non-coding genes included Ensembl
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non-coding and Noncode non-overlapping annotations. Ensembl t/ r/ sn/ sno/ mi/ misc-RNAs
were removed from the final list of non-coding RNAs, and RNA-Seq used only poly-T beads
selected RNAs for sequencing, so the list mainly contained long non-coding RNAs. For Pearson
correlation coefficient-based heat map visualization, the average FPKM of the three replicates
at each age were used to calculate the Pearson’s r values between different ages.

2.4 Results
Transcriptome of Protein Coding and Long Non-coding RNAs in Mouse Postnatal Liver
Development
RNA-Seq generated an average of 175 million (from 172 to 179 million) 100 bp paired end
reads per sample for the 36 samples from 12 different ages of day -2, 0, 1, 3, 5, 10, 15, 20, 25,
30, 45, and 60 (n=3) with a mean of 83% (from 75% to 88%) of the reads mapped to the mouse
reference genome (NCBI37/mm9). The mapped reads were annotated to protein coding genes
by Ensembl66 and non-coding genes by Ensembl66 and Noncode v3 as the reference
annotation databases. Because the sequencing libraries were constructed from poly-T bead
selected RNAs, the detected non-coding RNAs were mainly lncRNAs, but some small noncoding RNAs, such as tRNAs, rRNAs, snRNAs, snoRNAs, and miRNAs, were also detectable.
FPKM is used to represent gene expression level. The distribution of gene expression levels
revealed that the majority of lncRNAs were expressed at a lower level than protein coding
genes with a sharp distribution peak around FPKM=1 in all 12 ages. As an example, distribution
curves at day 5 are shown in Fig. 2.1. These lower expression levels were consistent with
previous reports in zebrafish and humans (Cabili et al., 2011b; Pauli et al., 2012), suggesting a
general property of lncRNAs. When the genes with FPKM > 1 in any age were considered as
the genes expressed during liver postnatal maturation, as showed in Table 2.1, a total of 15,244
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Table 2.1 Protein-coding and long non-coding genes expressed during liver postnatal
maturation
Gene class

Annotated
database

Total
annotated
genes

Expressed
in liver

Percentage
of
expressed
genes

Protein
coding
RNAs
Long noncoding
RNA

Ensembl66

23,196

12,990

56%

Ensembl66
Noncode
v3.0
Total
lncRNAs
Ensembl66

9,322
18,267

1,194
738

13%
4%

952
498

80%
67%

27,589

1,932

7%

1,450

75%

5,481

322

6%

56,266

15,244

27%

Other noncoding
RNA*
Total

Differentially Percentage
expressed
of
in liver
differentially
expressed
genes in
liver
10,768
83%

* Other non-coding RNAs include Ensembl66 annotated t-RNAs, r-RNAs, miRNAs, snRNAs,
snoRNAs, and miscRNAs
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(27%) genes among the 56,266 annotated mouse genes by both annotation databases were
expressed in liver over the 12 ages, including 12,990 (56%) protein-coding genes, 1,932 (%)
lncRNAs, and 322 other small non-coding RNAs.
Developmental Changes of Protein Coding and Long Non-coding RNAs in Mouse Postnatal
Liver Development
The Pearson correlation coefficient between any two samples of different ages was used to
assess the similarity and differences of gene expression profiles over the 12 ages (Fig. 2.2).
High correlation was found among the days, which correspond to liver development for perinatal
(day -2, 0), neonatal (day 1, 3, 5), adolescent (day 10, 15, 20, 25), and young adult (day 30, 45,
60) with significant changes between each developmental stage.
ANOVA tests identified 10,768 (83%) of the 12,990 expressed protein-coding genes and
1,450 (75%) of the 1,932 expressed lncRNAs, which had significantly differential expression
levels during postnatal liver development (Table 2.1).

Hierarchical clustering analysis was

performed on these differentially expressed genes to reveal their developmental expression
patterns (Fig. 2.3). Three major patterns were identified for both protein-coding (Fig. 2.3A) and
lncRNA genes (Fig. 2.3B) with Cluster 1, enriched at neonatal ages; Cluster 2, enriched at
adolescent ages; and Cluster 3, enriched at adult ages. The proportion of genes belong to each
pattern group was similar between protein-coding and lncRNA genes, with Cluster 1 as the
largest group (>70% of differentially expressed genes), followed by Cluster 3 and Cluster 2.
Genes in these three groups together accounted for over 95% of all differentially expressed
genes.
The emerging molecular functions of lncRNAs include regulation of gene expression in cis
(on neighboring genes) or in trans (distantly located genes) (Wang and Chang, 2011). One
expectation from the in cis regulation in our samples is that the expression of lncRNAs and their
neighboring gene loci should be correlated across the developmental ages to share the same
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cluster patterns. To test this, we analyzed the correlation of ontogenic expression patterns
between pairs of neighboring genes by examining the distribution of their correlation R values
(Fig. 2.4). As a control, the distribution of R value for 10,000 random selected protein-coding
gene (PC) pairs showed a peak around 0. Since the correlation of expression between a
lncRNA (NC) and its PC neighbor may result from a true cis effect of the NC on its PC neighbor,
or merely proximal transcriptional activity in the surrounding open chromatin, we also compared
the correlation between neighboring PC-PC and PC-NC pairs. Two different stringency levels
for selecting neighboring pairs were used. The lower stringency for PC-PC selected 21,300
pairs, including every nearest PC neighbor for every PC gene without filters, and the lower
stringency for PC-NC pairs selected 19,923 pairs, including every nearest PC neighbor for every
NC gene. The higher stringency limited neighboring gene pairs to a 10 kb distance from each
other, and at least one gene must be expressed, which reduced the number of pairs to the scale
of thousands. At low stringency, the distribution of correlation R for both PC-PC and PC-NC
pairs showed a peak around 0.2. At high stringency, which is a more reasonable criterion, the
distribution peak of R values for PC-NC was around 0.8, while that for PC-PC was still around
0.2. This result demonstrated that PC-NC neighboring genes tended to exhibit high correlation
in ontogenic expression patterns.
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Fig. 2.1

Fig. 2.1 Distribution of Gene Expression for Protein-coding and Long Nonconding
RNAs.
This figure uses data from the age of day 5 as an example, and the FPKM value for each gene
was the average FPKM of three individual animals
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Fig. 2.2

Fig. 2.2 The similarity of gene expression profiles between any two samples of
different ages represented by Pearson Correlation Coefficient.
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Fig. 2.3
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Fig. 2.3 Developmental gene expression patterns during postnatal liver maturation.
Heat maps are drawn for all significantly differentiated expressed protein-coding (A) and long
non-coding (B) genes during development in liver. Differential expressions were detected by
ANOVA with adjusted p-values < 0.05. For each gene, log2(FPKM+1) over the ages were
converted to z-scores, and the scale bar indicates z-score values. Genes are hierarchically
clustered, and the color bar on the right shows the major trends of gene expression: high
relative expression at early ages (neonatal, Cluster 1), intermediate ages (adolescent, Cluster 2)
and older ages (adult, Cluster 3). The number of protein-coding and long non-coding genes in
each major cluster are also listed on the right side.
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Fig. 2.4

Fig. 2.4 Distribution of Correlation R Value for Expression Patterns between Pairs of
Neighboring Genes.
Random are gene pairs selected at random; PC-PC All means every nearest PC (protein-coding)
neighbor for every PC gene; PC-NC All means every nearest PC neighbor for every NC (long
non-coding) gene; PC-PC Hi means PC-PC neighbor pairs within 10kb of each other, and at
least one gene in the pair is expressed; PC-NC Hi means PC-NC neighbor pairs within 10kb of
each other, and NC must be expressed. The number of gene pairs in each group is shown in
the parenthesis.
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Biological Interpretation of the Liver Developmental Transcriptome in Mouse Liver
In order to examine progress of liver functional maturation during postnatal development,
six ages from the four different developmental stages at day -2 (perinatal), day 1 and day 5
(neonatal), day 20 and day 25 (adolescent), and day 60 (adult) were selected to analyze the
liver transcriptome in more details. Day 60 was used as a matured reference transcriptome.
Gene expression at each of the younger ages was compared to that of day 60 samples for
differential expression. Statistically significant differential expression for both over-expressed
and under-expressed genes were identified in each younger age and Gene Ontology (GO)
analysis were performed to identify the most significantly affected pathways during liver
maturation.
Fig. 2.5A shows a heat map for GO categories with significantly over-expressed genes in
early ages. The numbers of over-expressed genes at each younger age compared to Day 60
were also listed. There was a clear developmental transition of enriched biological processes in
these over-expressed genes as indicated by the brackets B, C and D. GO categories in bracket
B were specific to perinatal and neonatal stages, and representative GO categories in this group
were listed in Fig. 2.5B. Enriched biological processes at this stage were mainly involved in cell
cycle and basic cellular metabolism, suggesting active cell proliferation in fetal and newborn
livers. GO categories involved in blood cell development and homeostasis also showed up at
this stage, which corresponded to the hematopoietic function of fetal liver.

Typical GO

categories in bracket C, which were specific to neonatal livers, were shown in Fig. 2.5C. The
major over-expressed pathways at this stage were related to blood cell generation and immune
activation. So the neonatal liver still retained residual hematopoietic function from fetal liver.
And with exposure to the environment after birth, the immune system became activated.
Representative GO categories enriched at day 20 were shown in Fig 2.5D, which were
pathways involved in tissue structure organization, and also include a few metabolic processes
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of alcohol and sulfur compounds. At day 25, there were no significant GO categories with gene
over-expression compared to day 60.
Fig. 2.6A shows a heat map for GO categories with significantly under-expressed genes in
early ages. The numbers of under-expressed genes at each younger age compared to Day 60
were also listed. There were fewer under-expressed genes as the age became closer to day 60.
Day 25 samples had very few significant GO categories, indicating the liver was quite mature at
this age.

The majority of pathways with gene under-expression were different kinds of

metabolic processes. One group of them matured relatively late during development (significant
under-expression until day 20, see bracket B in Fig. 2.6A), including metabolic processes of
isoprenoids, fatty acid, sterol, cholesterol, amine, organic acid, aromatic compounds, peptide,
glutathione and cellular modified amino acids (Fig. 2.6B). Under-expressed GO categories
specific to ages of day -2, 1 and 5 were biological processes involved in metabolic processes of
xenobiotics, tryptophan, vitamin, small molecule catabolism, and carboxylic acid biosynthesis,
as well as immuno response processes, such as humoral immune response, immune effector
process, leukocyte mediated immunity, T cell and B cell mediated immunity (Fig. 2.6C). The
representative GO categories that matured early during development (day 1) were listed in Fig.
2.6D, which included pathways of critical nutrients metabolism (glucose, lipid, and amino acids),
bile acids transport, and blood coagulation. These results revealed important details of hepatic
functional transition and maturation in postnatal liver development.
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Fig. 2.5
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Fig. 2.5

Fig. 2.5 Gene Ontology Analysis for Over-expressed Genes during Development
Compared to Day 60.
(A) Heat map for GO categories with significant gene over-expression at ages of day -2, 1, 5,
20 and 25. The color represents the false discovery rate (FDR) of each GO category. The
numbers on the right are the cumulative number of GO categories. The three brackets B, C and
D identify groups of GO categories enriched at specific ages during development.
Representative GO categories in each bracket are show in the corresponding panels of (B), (C)
and (D).
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Fig. 2.6

A
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Fig. 2.6

Fig. 2.6 Gene Ontology Analysis for Under-expressed Genes during Development
Compared to Day 60.
(A) Heat map for GO categories with significant gene under-expression at ages of day -2, 1, 5,
20 and 25. The color represents the false discovery rate of each GO category. The numbers on
the right are the cumulative number of GO categories. The three brackets B, C and D identify
groups of GO categories enriched at specific ages during development. Representative GO
categories in each bracket are show in the corresponding panels of (B), (C) and (D).
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2.5 Discussion
In this study, RNA-Seq analysis of liver developmental transcriptome at 12 ages in mice
resulted in two major findings. First, the developmental expression of lncRNAs in mouse liver
was characterized, which may play an important role in the regulation of liver maturation.
Second, the ontogenic expression patterns for protein-coding genes were defined, which
revealed the timeline for liver growth and functional transition during postnatal development.
In our data, approximately 40% of all annotated genes were found expressed in liver during
postnatal development. And around 80% of the expressed genes showed differential expression
across the ages, indicating a dynamic nature of developmental transcriptome. An interesting
result was that the majority of the genes showed decreased expression as the liver became
mature (Fig. 2.3A). Pathway analysis of the differentially expressed genes demonstrated that
most of the highly expressed genes at early ages belonged to diverse biological processes of
cell proliferation, basic cellular metabolism, cellular structure assembly, and hematopoiesis (Fig.
2.5B). However, as the age grew, the liver cells became more static and functionally more
specialized in metabolism. Thus the expressed genes changed to a more concentrated group.
Non-coding RNAs have been found to be pervasively expressed in the genome, and long
non-coding RNAs are an important class involved in a variety of biological functions. The
molecular mechanisms for long non-coding RNAs to regulate gene expression are largely base
on their ability to form complex secondary structures and specifically interact with proteins like
transcription factors and chromatin modifiers, either blocking or facilitating their activity in
transcription (Wang and Chang, 2011). Our result of long non-coding RNA ontogenic expression
patterns (Fig. 2.3B), which was the same as protein-coding RNAs, strongly suggested the
implication of long non-coding RNAs in regulation of hepatic gene transcription during postnatal
development. Neighboring protein-coding and long non-coding RNA pairs exhibited higher
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correlations in ontogenic expression than neighboring protein-coding gene pairs under the same
selection criteria, indicating that in cis regulation by lncRNAs may be an important mechanism
of developmental gene expression in mouse liver. This was the first attempt to explore the
potential role of long non-coding RNAs in liver maturation, which clustered long non-coding
RNAs into different pattern groups and provided foundations and clues for study of their
molecular functions.
Our GO analysis revealed the details of biological changes happened in liver. At perinatal
stage (day -2 to 5), the liver underwent rapid cell proliferation and growth. And blood cell
development was still active in liver (Fig. 2.5B). At neonatal stage (day 1 and 5), there were
extensive immune cell activations as the newborns were exposed to the environment and
started food intake, which introduced enormous challenges to the immune system. But the
immunity in liver was not matured at this stage (Fig. 2.6C), which may explain the common
diagnosis of sepsis in neonates (Diehl-Jones and Askin, 2003). At day 20, the liver went through
changes of cell adhesion and tissue structure maturation (Fig. 2.5D). Some metabolic pathways
were over-expressed at this age, and this might correspond to the cause of increased
resistance to certain drugs in young children (Pineiro-Carrero and Pineiro, 2004).Genes in most
metabolic processes were under-expressed at young ages (Fig. 2.6). And the ones that matured
at earlier ages were in pathways for the metabolism of the most critical nutrients, like glucose,
lipid and amino acids (Fig. 2.6D). The critical function of blood coagulation also matured
immediately after birth to prevent life-threatening hemorrhage. As the mice were usually weaned
and separated from the mother three weeks after birth, this was the time that most of the liver
functions became mature. And at day 25, very few genes were still differentially expressed
compared to day 60.
The functional maturation of the liver organ is the physiological base for the maturation of
Phase-I drug metabolizing enzymes. As we can see, there are dramatic functional transitions
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during postnatal liver development, especially in metabolic pathways, which suggested
significant changes in the expression of Phase-I enzymes. In the following chapters, we will
analyze the ontogeny of major Phase-I genes and explore possible regulatory mechanisms of
their developmental expression.
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Chapter 3 : RNA-Seq Reveals Dynamic Changes of mRNA Abundance
of Cytochrome P450s and their Alternative Transcripts during Mouse
Liver Development

3.1 Abstract
Cytochrome P450s are a superfamily of enzymes that have critical functions in liver to
catalyze the biotransformation of numerous drugs. However, the functions of most P450s are
not mature at birth, which can markedly affect the metabolism of drugs in newborns. Therefore,
characterization of the developmental profiles and regulatory mechanisms of P450 expression is
needed for more rational drug therapy of pediatric patients. An animal model is indispensable
for studying the mechanisms of postnatal development of the P450s. Hence we used RNA-Seq
to provide a “true-quantification” of mRNA expression of all P450s in mouse liver during
development. Liver samples of male C57BL/6 mice at 12 different ages from prenatal to
adulthood were used. Total mRNAs of the 103 mouse P450s displayed two rapid increasing
stages after birth, reflecting critical functional transition of liver during development. Four
ontogenic expression patterns were identified among the 71 significantly expressed P450s,
which categorized genes into neonatal-, adolescent-, adolescent/adult-, and adult-enriched
groups. The 10 most highly expressed subfamilies of mouse P450s in livers of adult mice were
Cyp2E, -2C, -2D, -3A, -4A, -2F, -2A, -1A, -4F, and -2B, which showed diverse expression
profiles during development. The expression patterns of multiple members within a P450
subfamily were often classified to different groups. RNA-Seq also enabled the quantification of
known transcript variants of CYP2C44, CYP2C50, CYP2D22, CYP3A25, and CYP26B1, and
identification of novel transcripts for CYP2B10, CYP2D26, and CYP3A13. In conclusion, this
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study reveals the mRNA abundance of all the P450s in mouse liver during development, and
provides a foundation for mechanistic studies in the future.

3.2 Introduction
Cytochrome P450s (P450s) have been identified in all domains of life: animals, plants, fungi,
protists, bacteria, archaea, and even viruses. More than 18,000 distinct P450 proteins are
known (Nelson, 2009). According to the genomic data base, there are 57 functional P450s
identified in humans, and 102 P450s in mice (Nelson et al., 2004). Genes encoding P450
enzymes, and the enzymes themselves, are designated as CYP, followed by a number
indicating the gene family, a letter indicating the subfamily, and another number for the
individual gene. For example, CYP3A4 is the P450 enzyme belonging to the gene family 3,
subfamily A, and designated as number 4. The current nomenclature guidelines suggest that
members of the same P450 family share >40% amino acid sequence identity, while members of
one subfamilies must share >55% amino acid sequence identity.
In the catalytic cycle of P450s, the heme iron converts between the states of ferric (Fe3+)
and ferrous (Fe2+), facilitating the essential electron transfer from the substrate to molecular
oxygen. The flavoprotein POR is a critical co-factor in this process as it directly passes the
electron from NADPH through FAD to FMN in the POR protein and finally to P450 enzymes. It is
the only electron donor for all microsomal P450s, and alteration in POR activity can affect P450catalyzed drug oxidation (Hart et al., 2008).
There are 18 families of human P450 enzymes. The vast majority of these enzymes, which
are found in families 1, 2, and 3, function in metabolism of xenobiotics, solely oxidizing
chemicals that are not normally constituents of the body. They are the most important phase I
drug-metabolizing enzymes, contributing ~80% of phase I reactions (Evans and Relling, 1999),
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in the forms of hydroxylation, epoxidation, heteroatom (S-, N-) oxygenation, heteroatom (O-, S-,
and N-) dealkylation, oxidative group transfer and so on. P450s in family 4 are involved mainly
in the metabolism of fatty acids and eicosanoids. And other families of P450s have important
roles in many endogenous pathways, such as steroidogenesis (e.g., CYP11/17/19),
biosynthesis of cholesterol and bile acids (e.g., CYP7/8/27), and metabolism of vitamin D and
retinoic acid (e.g., CYP24/26/27) (Parkinson and Ogilvie, 2008). Due to their broad substrate
specificity, it is possible that two or more P450s contribute to the metabolism of a single
compound, or a single P450 catalyzes two or more metabolic pathways for the same drug. Yet
sensitive probe substrates can also be found to monitor P450 activity, and specific enzyme
inhibitors can be used as controls for assessing enzymatic activities (Table 3.1). Previous
studies have demonstrated that the P450 mRNAs in family 1-4 are inducible by ligands of four
classes of xenobiotic receptors, namely the aryl hydrocarbon receptor (AhR), the constitutive
androstane receptor (CAR), the pregnane X receptor (PXR), and the peroxisome proliferatoractivated receptor alpha (PPARα) (Petrick and Klaassen, 2007). Although these receptors have
overlapping targets, it is generally considered that AhR is responsible for the mRNA induction of
family 1, CAR for family 2, PXR for family 3, and PPARα for the mRNA induction of family 4 of
P450s. P450 induction may be associated with a loss of therapeutic effectiveness, which is a
particular concern when using drugs that have a narrow therapeutic index and treating a lifethreatening illness. The function, inhibition and inducibility of mouse and human P450 orthologs
are quite conserved. Table 3.1 listed examples of specific substrate reactions and inhibitors of
P450 enzymes in mice (Bogaards et al., 2000; Hrycay and Bandiera, 2009).
P450s catalyze the oxidation of organic substances, including the biotransformation of
numerous endobiotics (e.g. steroids, fatty acids, and eicosanoids) as well as the detoxification
or bioactivation of a variety of xenobiotics (e.g. drugs, chemical carcinogens, and environmental
contaminants) (Nebert and Gonzalez, 1987; Danielson, 2002). P450s are the major enzymes
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Table 3.1 Specific substrate reactions and inhibitors of P450 enzymes in mice

P450 Enzymes

Characteristic Metabolic Reaction

Inhibitors

CYP1A2

Methoxyresorufin O-demethylation

Furafylline

CYP2A5

Coumarin 7-hydroxylation

8-Methoxypsoralen

CYP2B10

Pentoxyresorufin O-depentylation

Pilocarpine

CYP2C29

Tolbutamide p-methyl hydroxylation

Menadione

CYP2D22

Bufuralol 1’-hydroxylation

Quinine

CYP2E1

4-Nitrophenol ortho-hydroxylation

4-Methylpyrazole

CYP3A11

Testosterone 6β-hydroxylation

Ketoconazole

CYP4A12

Arachidonic acid ω-hydroxylation

HET0016
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involved in the metabolism and bioactivation of drugs, accounting for about 75% of drug
biotransformation (Guengerich, 2008). Liver expresses the largest number of individual P450
enzymes (Hrycay and Bandiera, 2009). However, most P450s in the liver are expressed at low
levels at birth. The expression of P450s changes during liver development, which has been
categorized into several different developmental patterns, and considerable interindividual
variability occurs in the immediate postnatal period (Hines and McCarver, 2002; Hines, 2007).
Low P450 expression in liver during postnatal development is thought to be responsible for the
substantial pharmacokinetic differences between newborns and adults, and thus contributes to
differences in therapeutic efficacy and adverse drug reactions in pediatric patients (Blake et al.,
2005; Hines, 2008). One example is that the low CYP3A4 in neonatal livers results in a low
capacity to oxidize cisapride, which can result in QT prolongation in pediatric patients (Pearce et
al., 2001; Treluyer et al., 2001). An in-depth understanding of the regulation of the ontogeny of
human P450s is needed for safer and more effective drug therapy for pediatric patients.
The paucity of suitable tissue samples and limitations due to ethical and technical issues
have made it difficult to study the mechanisms controlling the ontogenic expression of P450s in
human liver (Rowell and Zlotkin, 1997). Animal models would be advantageous in overcoming
these difficulties and minimizing the influence of genetic variations and the environment. In
recent years, the mouse and rat have surpassed many other laboratory animals as the
experimental models of choice for the study of physiology, metabolism, and disease
(Muruganandan and Sinal, 2008; Hrycay and Bandiera, 2009). Advantages of these models
include rapid growth, easy maintenance, and the development of genetic manipulation
techniques for mechanistic studies with gain-of-function and loss-of-function strategies. Several
researchers have examined the ontogenic gene expression profiles of a few P450s in mouse or
rat liver (Choudhary et al., 2004; Alcorn et al., 2007; Cherala et al., 2007; Hart et al., 2009; Li et
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al., 2009a). Developmental expression patterns of some P450s in mice and rats are similar to
that in humans.
Previous studies quantified P450 gene expression at the mRNA level by either microarrays
or multiplex suspension arrays (Hart et al., 2009; Li et al., 2009a), which only provides relative
quantification of a given P450. These technologies detect mRNA levels by probe hybridization
and fluorescence signal intensity, which cannot compare expression levels among various
P450s, because different probes may have different hybridization efficiency. With the
development of next-generation sequencing technology, RNA-Seq can define a transcriptome
with low levels of background noise, no upper limit for quantification, and a high degree of
reproducibility for both technical and biological replicates (Mortazavi et al., 2008; Nagalakshmi
et al., 2008). More importantly, compared to microarrays, RNA-Seq quantifies the true
abundance of mRNA molecules in biological samples, and enables the comparison of
expression levels of all genes (Malone and Oliver, 2011). Furthermore, RNA-Seq has the power
to quantify expression levels of alternative transcripts of the same gene and to identify novel
transcripts efficiently (Pan et al., 2008; Wang et al., 2008; Malone and Oliver, 2011). In the
current study, RNA-Seq was used to systematically quantify the abundance of 103 mouse P450
mRNAs in liver during development to define the ontogenic profiles of these P450 mRNAs, with
an additional focus on the identification and quantification of alternative transcripts. Therefore,
the purpose of this study was to generate comprehensive information on the ontogeny of the
mRNAs of the P450 family of enzymes in the livers of mice, which will provide a foundation for
determining the regulatory mechanisms controlling the various transcription patterns of P450s
during liver development.

3.3 Materials and Methods
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Animals, Total RNA Extraction, Sequencing Library Construction, and RNA-Seq
The source and breeding of animals, RNA extraction, library construction, RNA-Seq and
FASTQ data file collection were the same as those in Chapter 2.
RNA-Seq Data Analysis
The RNA-Seq reads from the FASTQ files were mapped to the mouse reference genome
(NCBI37/mm9) and the splice junctions were identified by TopHat 1.2. The output files in BAM
(binary sequence alignment) format were analyzed by Cufflinks 1.0.3 to estimate the transcript
abundance (Trapnell et al., 2010).
Data Visualization and Statistics
The P450 genes (103 in total) were retrieved from Cufflinks output for further analysis.
Significant gene expression was determined by the drop-in-deviance F test of the fitted FPKM
data to a generalized linear model with a Poisson link function, a statistic designed to measure
the significance of a gene’s measured FPKM value relative to a zero FPKM value. The p-values
were adjusted for extra Poisson variation and corrected for false discovery by the BenjaminiHochberg method (FDR-BH) with a threshold set at 0.05 for significant expression (Benjamini
and Hochberg, 1995). A two-way hierarchical clustering dendrogram was generated by JMP
(version 9.0; (SAS Institute, Cary, NC) to determine the expression patterns of the P450 mRNAs
during liver development.
Validation of Alternative mRNA Transcripts
Alternative splicing events in the CYP2B10 and CYP2D26 were validated by reverse
transcription and end-point PCR. Total RNA (5 μg) was reverse-transcribed with M-MLV reverse
transcriptase (Invitrogen, Carlsbad, CA) and random primers in a final volume of 50 μl. Endpoint PCRs with reaction volumes of 20 μl were performed. Primer sequences are listed in
Table 3.2. The PCR products were separated on a 2% agarose gel. Bands of the expected
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sizes were excised and purified with a Qiagen QIAquick gel extraction kit (Valencia, CA).
Subsequently, DNA was sequenced with sequencing primers (Table 3.2) by ACGT Inc.
(Wheeling, IL). The alternative polyadenylation of CYP3A13 mRNA was validated by Rapid
Amplification of cDNA 3’-End (3’RACE) using RNA ligase-mediated rapid amplification of cDNA
ends (FirstChoice RLM-RACE kit; Ambion Inc., Austin, TX) as described before (Li et al., 2012).
Primer sequences are shown in Table 3.2.

3.4 Results
Total Expression and Proportions of Individual P450s during Liver Development
RNA-Seq generated an average of 175 million 100 bp paired-end reads per sample for the 36
samples from 12 different ages (n=3). More than 80% of the reads from each sample were
mapped to the mouse reference genome (NCBI37/mm9) by TopHat 1.2 (data not shown). The
FPKM values were highly reproducible in the triplicate samples at each age as indicated by the
small standard errors. If the Benjamini-Hochberg adjusted drop-in-deviance F-test p-value
(FDR-BH) in at least one of the 12 ages were less than 0.05 for a P450 gene, then that gene
was considered to be expressed in liver during development. Of the 103 mouse P450s, 71
genes were expressed during liver development.
Total FPKM values of all P450 mRNAs increased about 25-fold during postnatal liver
development from day -2 (479) to day 60 (12,345), with two surges followed by a plateau stage
after each surge (Fig. 3.1A). Fig. 3.1B shows the composition of the P450s, represented as
percentage of the total P450 mRNA FPKM, at the beginning and end ages of these surge and
plateau stages, i.e. day -2, 1, 10, 20, and 60. The first surge occurred from day -2 (FPKM, 479)
to day 1 (5,926) with more than a 10-fold increase of total P450 mRNA FPKM values. During
the first surge, the top 10 highly expressed P450 genes changed dramatically, with only 2 genes
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Table 3.2 Primer sequences for validation of novel transcripts identified by RNA-Seq
Gene

Cyp2b10

Method
End-point
PCR

Amplification

Sequence (5' to 3')

F:
From exon 6 to exon 9
ATGGCTTCCTGCTCATGCTCAAGT
(including
cassette
R:
exon)
GACAAATGCGCTTTCCCACAGACT

Sequencin
From exon 7 to exon 9
g
End-point
PCR

From exon
cassette exon

5

Sequencin From exon
g
cassette exon

6

Cyp2d26
End-point
PCR

cDNA synthesis

Outer PCR
Cyp3a13 3' RACE
Inner PCR

Sequencing

8

to

520 bp

TGATTGACCTGTTCATGGCAGGGA

F:
From cassette exon to TACAAGAGAAGGTGCTCAGAGGCT
exon 9
R:
TAGGGCTCTGGAGTAACTGGCATT

Sequencin From exon
g
cassette exon

411 bp

AGTGCCACACAGAGTGACCAAAGA

F:
to ACTACACATCCCTGGTTTGCCTGA
R:
AGCCTCTGAGCACCTTCTCTTGTA
to

PCR
product

CATGAAGGCCTCGTGCTTCACAAA
GCGAGCACAGAATTAATACGACTC
ACTATAGGT12VN
F:
AAGTTGCTCTTGTCAGAGTCCTGC
R:
GCGAGCACAGAATTAATACGACT
F:
CACTGTCCAGCCTTGTAAGGAAAC
R:
CGCGGATCCGAATTAATACGACTC
ACTATAGG
AAGTTGCTCTTGTCAGAGTCCTGC
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327 bp

(Cyp2d22 and Cyp2d10) in the top 10 P450s at both day -2 and day 1. During the first plateau
stage, although the total P450 mRNA FPKM values were relatively constant between day 1 and
10, the individual P450 mRNAs were altered, with CYP2E1 the most abundant at day 10. The
second surge occurred between day 10 and 20, with nearly a 2-fold increase of total P450
FPKM values from 6,139 to 11,087. The individual P450 mRNAs, which increased during the
second surge from day 10 to 20, were similar, because 6 P450s appeared at both ages in the
top 10 highly expressed P450s, and the top 3 are the same in an order of CYP2E1, CYP3A11,
followed by CYP2D26. During the second plateau stage of day 20 to 60, the individual P450
mRNAs continued to change, and became more diverse. At day 60, the top 10 highly expressed
P450s consisted of only 74% of the total P450 mRNAs, and many additional P450s were
expressed.
Expression Patterns of P450 Genes during Liver Development
P450 genes with a maximum over minimum expression ratio less than two among the twelve
studied ages were to be excluded for this party of the study. The data indicate that all 71
significantly expressed P450 genes had larger than two-fold differences in expression during
development. Two-way hierarchical clustering analysis of the 71 P450 genes revealed 4 distinct
Groups (Fig. 3.2A). The sum of the FPKM values in each group was plotted against age in Fig.
3.2B. Group 1 (neonatal-enriched) contained CYP2D26, CYP3A16, CYP3A41a/b, CYP3A44,
CYP4A10, CYP4A14,CYP4A31, CYP4A32, CYP4F16, CYP4F18, CYP4F39, CYP20A1, and
CYP39A1. The P450 genes in this group increased markedly after birth and reached a peak
around day 1 of age, and then decreased and remained relatively low after day 30. Group 2
genes (adolescent-enriched) consisted of CYP2A22, CYP2B9, CYP2B13, CYP2B23, CYP2C37,
CYP2C40, CYP2C68, CYP2C69, CYP2D37-ps, CYP2E1, CYP2G1, CYP4F15, CYP7A1, and
CYP26B1. The P450 genes in this group increased rapidly after birth, reached maximal
expression around day 20, and then decreased to lower levels in adult mice. Group 3 genes
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(adolescent/adult-enriched) included CYP1A2, CYP2A4, CYP2A5, CYP2A12, CYP2B10,
CYP2C29, CYP2C39, CYP2C50, CYP2C54, CYP2C55, CYP2C70, CYP2D22, CYP2J6,
CYP3A13, CYP3A25, CYP3A59, CYP4B1, CYP4F14, and CYP17A1. The mRNA of the P450s
in this group were expressed at very low levels at birth, but increased substantially between day
10 and 25, and reached a plateau in adult mice. Group 4 P450s (adult-enriched) consisted of
CYP2C38, CYP2C44; CYP2C67, CYP2D9, CYP2D10, CYP2D11, CYP2D12, CYP2D13,
CYP2D34, CYP2D40, CYP2F2, CYP2J5, CYP2R1, CYP2U1, CYP3A11, CYP4A12A/B,
CYP4F13, CYP4V3, CYP7B1, CYP8B1, CYP26A1, CYP27A1, and CYP51. The P450s in this
group were expressed lowly 2 days before birth, gradually increased after birth with a rapid
increase around 25 days of age, and reached highest expression in adults (45 and 60 days of
ages). The largest correlation distance with respect to neighboring ages for the four groups (as
shown by the clade separation on the dendrogram scale) was observed between 20 and 25
days of age.
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Fig. 3.1
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Fig. 3.1 Total Expression and Proportions of Individual P450s during Liver
Development.
(A) Total mRNAs of the 103 mouse P450 genes in liver during development. RNA-Seq was
done for liver mRNAs of male C57BL/6 mice at 12 ages from 2 days before birth to 60 days
after birth. The FPKM values of all 103 mouse P450 genes at each age were added and plotted
to show the developmental pattern of total P450 mRNAs. Bars represented the mean ± S.E.M.
of three individual animals. (B) Individual P450 mRNAs (shown as percentages of total P450
mRNAs) at 2 days before birth and 1, 10, 20, and 60 days after birth. Each gene is presented in
a unique color for all ages. Only the top 10 P450 mRNAs at each age are listed in alphabetical
order, and the rest were grouped as “Others.”
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Comparison of Transcript Abundance of Some P450 Subfamilies during Liver Development
The 103 mouse P450 genes belong to 16 families and 39 subfamilies. Ontogenic patterns
of the major P450 subfamilies in liver are summarized in Fig. 3.3.
CYP1A subfamily. The CYP1A subfamily has two members, CYP1A1 and CYP1A2.
CYP1A1 mRNA was expressed at very low levels in liver at all ages. CYP1A2 had a
developmental pattern belong to group 3 (adolescent/adult-enriched) (Fig. 3.3A).
CYP2A subfamily. The CYP2A subfamily consists of five members, CYP2A4, CYP5,
CYP12, CYP22, and CYP2AB1. Except for CYP2AB1, the other four genes in liver were
expressed with the adolescent or adolescent/adult-enriched patterns (Fig. 3.3B).
CYP2B subfamily. The CYP2B subfamily contains five members, CYP2B9, -10, -13, -19,
and -23. CYP2B9 and CYP2B13 contributed the most to the expressed levels of this subfamily
with an adolescent-enriched pattern (Fig. 3.3C).
CYP2C subfamily. The CYP2C subfamily includes 16 members, CYP2C29, -37, -38, -39, 40, -44, -50, -53-ps, -54, -55, -65, -66, -67, -68, -69, and -70. CYP2C29, -37, -50, -69, and -70
were the most highly expressed members in this P450 subfamily in livers of mice. CYP2C69
was neonatal-enriched, CYP2C37 was adolescent-enriched, and CYP2C29, -50, and -70 were
adolescent/adult-enriched (Fig. 3.3D).
CYP2D subfamily. The CYP2D subfamily consists of 10 members, CYP2D9, -10, -11, -12, 13, -22, -26, -34, -37-ps, and -40. Three genes, CYP2D9, -10, and -26, were expressed to a
higher extend than the other CYP2D genes. CYP2D26 increased remarkably after birth and
remained at a consistent level until day 20, and decreased after 30 days of age (neonatalenriched). CYP2D9 was expressed lowly until day 20 and increased markedly to reach a
plateau at 30 days of age (adolescent/adult-enriched). CYP2D10 increased gradually
throughout development (Fig. 3.3E).
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Fig. 3.2 Expression Patterns of P450 Genes during Liver Development.
(A) Hierarchical clustering of expression profiles for 71 significantly expressed P450 mRNAs in
livers of male C57BL/6 mice. Significant expression was determined by the FDR-BH with a
threshold of _0.05. The two trees describe the relationship between different gene expression
profiles (right tree) and various ages (bottom tree). The dendrogram scale represents the
correlation distances. Average FPKM values of three replicates per age are given by colored
squares: red, relatively high expression; blue, relatively low expression. The dashed lines
categorize the expression profiles into four groups. (B) Changes in total FPKM values of the
P450 mRNAs in each group on the basis of the hierarchical clustering in A through different
ages during development. Bars represent the mean ± S.E.M. of three individual samples.
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CYP2E subfamily. The CYP2E subfamily has only one member, CYP2E1, which was one
of the most abundant P450s expressed in liver. CYP2E1 increased sharply from day -2 to day 5,
and then continually increased to a peak at day 20, followed by a decrease and then increase to
a consistently high level thereafter (Fig. 3.3F).
CYP2F subfamily. The CYP2F subfamily also contains only one member, CYP2F2, which
was expressed at a low level until 15 days of age and thereafter gradually increased (Fig. 3.3G).
CYP3A subfamily. The CYP3A subfamily includes 9 members, CYP3A11, -13, -16, -25, 41A, -41B, -44, -57, and -59. CYP3A11 was the most abundantly expressed gene in this
subfamily, which gradually increased throughout postnatal development (Fig. 3.3H). Several
CYP3A members, including CYP3A16, -41A, -41B, and -44, were neonatal-enriched with the
highest expressed levels around 5-days of age (Fig. 3.3H).
CYP4A subfamily. The CYP4A subfamily has 8 members, CYP4A10, -12A, -12B, -14, -29ps, -30b-ps, -31, and -32. Four members in this subfamily, CYP4A10, -14, -31, and -32, had a
neonatal-enriched expression pattern with the highest expression at 1 day of age. The other two
members, CYP4A12A and CYP4A12B, were not expressed until day 30, and then increased
rapidly in adult mice (Fig. 3.3I).
CYP4F subfamily. The CYP4F subfamily contains 9 members, CYP4F13, -14, -15, -16, -17,
-18, -39, -40, and -41-ps. CYP4F13, -14, and -15 were expressed in liver and they appeared to
have an adolescent or adolescent/adult enriched pattern (Fig. 3.3J). CYP4F16, -18, and -39
were also expressed, but at very low levels.
Ontogeny of Known Transcript Variants of P450s during Liver Development
Among the 103 mouse P450 genes, six have known alternative transcripts annotated in the
NCBI database, including CYP1A1 (two isoforms), CYP2C44 (two isoforms), CYP2C50 (three
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Fig. 3.3
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Fig. 3.3 Expression Patterns of the Selected P450 Subfamilies during Liver
Development.
(A) CYP1A; (B) CYP2A; (C) CYP2B; (D) CYP2C; (E) CYP2D; (F) CYP2E; (G) CYP2F; (H)
CYP3A; (I) CYP4A; and (J) CYP4F. Data are presented as mean FPKM ± S.E.M. of three
individual samples.
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isoforms), CYP3A25 (two isoforms), and CYP26B1 (two isoforms). CYP1A1 was expressed
very lowly in liver. RNA-Seq was able to provide the ontogenic patterns of the annotated
alternative transcripts of the five P450 genes that were significantly expressed in liver (Fig.
3.4A-E).
For the two CYP2C44 transcripts, NM_001167905 lacks the last exon of NM_001001446
and has an alternative polyadenylation site. NM_001001446 was the major isoform in mouse
liver throughout development. Its mRNA was high at birth and reached a peak around 5 and 10
days of age, decreased between 10 and 20 days of age, and increased again and reached a
high expression plateau after 45-days of age (Fig. 3.4A). NM_001167905 was not expressed
throughout liver development.
Cyp2c50 has three transcripts. NM_001167875 lacks the fifth exon of NM_134144.
NM_001167877 is a truncated isoform with the coding region containing only the first 4 exons of
NM_134144. NM_134144 was the major isoform in mouse liver throughout development. Its
expression profile was a typical Group 3 pattern (adolescent/adult-enriched) (Fig. 3.4B).
NM_001167875 and NM_001167877 were very lowly expressed throughout liver development.
The two CYP2D22 transcripts encode the same protein, but NM_019823 has 6 less
nucleotides at the end of the first exon than NM_001163472, which results in a shorter 5’-UTR.
NM_019823 was the major transcript of Cyp2d22 expressed throughout liver development. The
mRNA of NM_019823 increased rapidly from 2 days before birth to 3 days after birth, and then
remained relatively consistent with a small peak at 20-days of age. The mRNA of
NM_001163472 remained consistently low at all ages (Fig. 3.4C).
Cyp3a25 has two transcripts. NR_030782 is a non-coding RNA with a skipped sixth exon of
NM_019792. The expression profiles of these two transcripts were similar during development,
but NM_019792 had higher expression levels at all postnatal ages. Both transcripts had a “day
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Fig. 3.4

Fig. 3.4 The mRNAs of Known Alternative Transcripts of Five P450s that Were
Significantly Expressed during Liver Development.
(A) CYP2C44; (B) CYP2C50; (C) CYP2D22; (D) CYP3A25; and (E) CYP26B1. The transcripts
are labeled with their NCBI transcript identification number. Data are presented as mean FPKM
± S.E.M. of three individual samples.
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1 surge”, which decreased markedly by 5 days of age and then rapidly increased between 10
and 20 days of age, and reached a plateau at 20 days of age (Fig. 3.4D).
The two CYP26B1 transcripts encode the same protein, but have different transcription
start sites. NM_001177713 is shorter than NM_175475 in the 5’-UTR. Both transcripts were
expressed at very low levels during mouse liver development (Fig. 3.4E).
Identification of Novel Transcripts of P450s in Liver by RNA-Seq
Potential novel transcripts of P450s, which are not annotated in the NCBI database, were
identified

by

examining

sequencing

results

in

the

UCSC

genome

browser

(http://genome.ucsc.edu/cgi-bin/hgGateway). Alignment results from TopHat were converted to
BigWig files and uploaded to the browser to display the distribution of reads in the genome.
Junction files were also used to determine alternative splicing events. In the browser, each
junction consists of two connected blocks, where each block is as long as the maximal
overhang of any read spanning the junction. The score is the number of alignments spanning
the junction.
The Cyp2b10 RefSeq gene in assembly of NCBI37/mm9 was located on chromosome 7
between 26,682,683 and 26,711,643 with 9 exons. A tiny peak of read alignment between the
peaks of exon 8 and 9 was observed around chromosome position 26,710,000 in the Bigwig
view (Fig. 3.5A). Two junctions with a score of 3 indicated alternative splicing events that could
generate a cassette exon in this region. The cassette exon was validated by endpoint PCR
using cDNAs from two liver samples of 60-day-old mice. The forward PCR primer mapped to
exon 6 and the reverse PCR primer mapped across the junction between the cassette exon and
exon 9 (Table 3.1), which produced an amplicon containing the cassette exon with a size of 411
bp in all samples examined (Fig. 3.5A). Sequencing of the PCR product revealed the presence
of a 31-bp cassette exon, which could alter the protein translation reading frame when retained
in the transcript.
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Fig. 3.5 Identification of Novel Transcripts of P450s in Liver by RNA-Seq.
(A) Identification of a cassette exon in CYP2B10 mRNA. (B) Identification of a cassette exon in
CYP2D26 mRNA. (C) Identification of an alternative polyadenylation site in CYP3A13 mRNA.
RNA-Seq reads of a day 60 sample were aligned to the reference genome mm9 by TopHat and
viewed as distribution peaks by the UCSC genome browser. Output junction reads from TopHat
are also shown. The cassette exons or alternative polyadenylation was validated by endpoint
PCR or 3’-RACE. The PCR products are shown by gel electrophoresis and further sequenced
by single-pass DNA sequencing with a designed primer. The sequence was aligned back to the
P450 gene regions.
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A similar cassette exon peak and alternative splicing junctions were also found in the
browser view of the Cyp2d26 gene, which is located on the minus strand of chromosome 15
between 82,620,537 and 82,624,675 (Fig. 3.5B). The cassette exon was located between exon
7 and 8, and validated by endpoint PCR with two sets of primers. Primer set 1 bound to exon 5
and the cassette exon, which amplified a fragment with an expected size of 520 bp. Primer set 2
bound to the cassette exon and exon 9, which amplified a fragment with an expected size of
327 bp. The cassette exon sequence contained 42 nucleotides, which would change the protein
product if retained in the transcript.
Thirteen peaks of sequencing reads were observed along the RefSeq Cyp3a13 gene. The
first twelve exons were covered by a single peak. However, in exon 13, a region with high-level
reads followed by a region with low-level reads was found. A sharp decrease in the sequencing
reads occurred around chromosome position 138,335,200 in the 3’-UTR of Cyp3a13 (Fig. 3.5C).
The RNA-Seq reads ended at coordinate 138,334,161 of chromosome 5, which matched with
the termination of this gene in the reference sequence. This suggested an alternative
polyadenylated mRNA transcript in the 3’-UTR region of Cyp3a13. To validate the shorter 3’UTR transcript, we performed 3’RACE-PCR with two RNA samples from livers of 60-day old
mice. The forward PCR primers, shown in Fig. 3.5C, together with reverse primers provided by
the RLM-RACE kit, generated a band that was sequenced using the Cyp3a13-specific
sequencing primer (Table 3.1). Sequencing results revealed a poly(A)-containing sequence that
uniquely mapped to the 3’-UTR of Cyp3a13. Termination of the shorter 3’-UTR transcript
occurred at chromosome location 138, 336,180, which was more than 2kb upstream of the end
of the reference gene sequence. In addition, an AATAAA sequence was noted at 23 bases
upstream of the termination site, which might serve as a recognition signal for the poly(A)
polymerase complex.
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3.5 Discussion
In the current study, RNA-Seq was used to truly quantify mRNA abundance of the 103
P450 genes in mouse liver during postnatal development. Compared to other commonly used
methods for RNA quantification, such as microarray, branched DNA, or real-time PCR, RNASeq directly counts sequence reads of the nucleotide molecules in biological samples, which is
the only method for true quantification of mRNA expression. Expression of a transcript is
represented by FPKM (fragments per kilobase of exon per million reads mapped), which
normalizes sequencing depths between different samples and sizes between various genes,
allowing direct comparison of mRNAs among various transcripts in a genome-wide scale. As
shown in Fig. 3.1, the quantitative abundance of mRNAs encoded by the 103 P450 genes was
determined in mice at 12 ages, which has not been reported previously.
From perinatal through neonatal to adult life, the total FPKM values of all P450 genes
increased about 25 fold with two rapidly increasing stages (Fig. 3.1A). The first surge occurred
from 2 days before birth to 1 day after birth. Not only the total abundance, but also the
composition of expressed P450s was markedly altered during this period, when the pup was
born and lost the direct physiological connection with the mother. Multiple hormones were
known to influence the expression of drug metabolizing enzymes. During pregnancy, maternal
hormones cross the placenta into the baby. After birth, the loss of maternal hormones may be a
contributing factor to the changes in the expression of some P450s. The new born mice also
began to be exposed to the environment, which contains all kinds of xenobiotics. A critical
function of P450s is xenobiotic metabolism, thus the first surge of P450 expression may provide
protections to the newborns against environmental toxic compounds. The second surge
occurred from day 10 to day 20, with a rapid increase in abundance of the P450 mRNAs. But
the expression of each P450 was similar from 10 to 20 days of age, as the expression of most
P450s increased simultaneously. This period is also the most rapidly growing stage of postnatal
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liver development, as studies have shown that cell proliferation in mouse liver is high until 20
days of age, and then the hepatic architecture begins to resemble the adult liver (Apte et al.,
2007).
Hierarchical clustering of significantly expressed P450s revealed four hepatic ontogenic
expression patterns (Fig. 3.2). The expression profiles of these patterns were similar to a
previous study of P450 ontogeny in mice (Hart et al., 2009), with some genes enriched at
younger ages and some enriched at older ages. However, the previous study examined only a
few P450s, whereas the present study included all the expressed P450s in the liver of mice, and
therefore generated a more comprehensive summary of ontogenic patterns. Whereas, the
earlier study concluded there were three patterns of P450 ontogeny in livers of mice (Hart et al.,
2009), the present study concludes there are four patterns. Clustering of the P450s from 12
developmental ages indicates that the largest correlation distance with respect to neighboring
ages is between 20 and 25 days of age, which spanned the period when the diet changes from
milk to chow. Because P450s have important functions in metabolizing chemicals absorbed
from the gastrointestinal tract, it is reasonable to anticipate this change in P450 expression with
a change in food intake.
The most highly expressed P450 mRNAs in liver of mice were from the CYP1-4 families,
which belong to the xenobiotic-metabolizing P450s. They displayed changes in expression
during development. Some P450 subfamilies were primarily expressed during the neonatal
stage, whereas others were mainly expressed during the adolescent or adult stage of
development. Even within each subfamily, individual members were expressed with various
developmental patterns. In the CYP2D subfamily, CYP2D26 mRNA reached its maximum
expression during the neonatal period, whereas CYP2D9 reached its maximum expression
during the adolescent/adult period (Fig. 3.3E). Similarly in the CYP3A subfamily, CYP3A16,
CYP3A41A, CYP3A41B, and CYP3A44 were maximally expressed during the neonatal period,
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whereas CYP3A11 was maximally expressed in the adult mice (Fig. 3.3H). A similar
developmental switch also exists in human CYP3A enzymes (Schuetz et al., 1994; Stevens et
al., 2003; Leeder et al., 2005). Thus mice might serve as a good model to study the
mechanisms controlling the developmental switches of P450 expression in liver. Of note, it is
difficult to directly compare our data in mice with other previously published data in humans. Our
study determined levels of mRNA transcripts of P450s, whereas most other published studies
determined protein concentrations and enzyme activities of human P450s.
Because RNA-Seq has the ability to examine the transcriptome at the resolution of a single
base (Wang et al., 2009), it can quantify the mRNAs of genes as well as their individual
transcript variants (Fig. 3.4). The known transcript variants of the P450s might be translated into
different proteins, as in CYP2C44 and CYP2C50, or those that differ only in the UTR regions of
the transcripts, as in CYP2D22 and CYP26B1. Because transcript variants can alter protein
functions, mRNA stability, subcellular localization, and translation efficiency of the transcripts
(Pesole et al., 2000), identification of the predominant transcripts of P450s and their
developmental expression patterns might help to predict variations in protein activity.
Research has shown that 92-94% of human genes undergo alternative splicing, promoter
usage, and polyadenylation (Wang et al., 2008). Only six out of the 103 mouse P450 genes in
the NCBI database have annotated transcript variants, so alternative splicing P450 transcripts in
mice is probably an underexplored area. With the advantage of RNA-Seq, the present study
identified several novel transcript variants in CYP2B10 and CYP2D26, even though they are
expressed at very low levels (very small peaks in BigWig view of Fig. 3.5A and 3.5B). When the
cassette exons are translated, the resultant P450 enzymes will have different protein sequences,
which might lead to a difference in enzyme activities. The CYP3A13 transcripts, with the shorter
3’-UTR, appeared to be the predominant transcript of this gene. A similar shorter 3’-UTR
transcript has been reported for the human CYP3A4 gene (Li et al., 2012). Although the
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CYP3A4 transcript with shorter 3’-UTR doesn’t change amino acid sequences, it is more stable
and can translate to protein more efficiently than the CYP3A4 transcript with the longer 3’-UTR
(Li et al., 2012). The mouse Cyp3a13 gene might serve as a model to study how alternative
polyadenylation events are regulated. Further studies are needed to investigate the functional
significance of these novel transcripts.
P450 proteins and enzyme activities were not determined in this study due to technique
limitations. Specific antibodies against most of the mouse P450 proteins, specific substrates,
and inhibitors of many individual mouse P450 enzymes are not available. Technological
breakthroughs in proteomics and metabolomics are essential to study the ontogeny of P450
proteins.
In summary, the present study describes the ontogeny of the mRNAs of all P450s in the
mouse liver during development. These data provide the fundamental knowledge for studying
mechanisms of regulation of the transcription of P450 genes in liver during development. A
previous study from our laboratories indicates that the developmental regulation of Cyp3a gene
expression in mouse liver may be due to dynamic changes of histone modifications during
postnatal liver maturation (Li et al., 2009b). No doubt, epigenetics and various hepatic
transcription factors play an important role in regulating ontogenic expression of P450 enzymes
(Kyrmizi et al., 2006). Studies on the networking of transcription factors and epigenetic
signatures in liver may shed light on the regulatory mechanisms of the observed P450
developmental patterns. These mechanisms may be of considerable importance in
understanding the kinetics of xenobiotic metabolism during the neonatal period.
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Chapter 4 : RNA-Sequencing Quantification of Hepatic Ontogeny of
Phase-I Enzymes in Mice

4.1 Abstract
Phase-I drug metabolizing enzymes catalyze reactions of hydrolysis, reduction, and
oxidation of drugs and play a critical role in drug metabolism. However, the functions of most
Phase-I enzymes are not mature at birth, which markedly affect drug metabolism in newborns.
Therefore, characterization of the expression profiles of Phase-I enzymes and the underlying
regulatory mechanisms during liver maturation is needed for better estimation of using drugs in
pediatric patients. Mouse is an animal model widely used for studying the mechanisms in the
regulation of developmental expression of phase-I genes. Therefore, we applied RNA
sequencing to provide a “true quantification” of the mRNA expression of Phase-I genes in
mouse liver during development. Liver samples of male C57BL/6 mice at 12 different ages from
prenatal to adulthood were used for defining the ontogenic mRNA profiles of Phase-I families,
including hydrolysis: carboxylesterase (Ces), paraoxonase (Pon), epoxide hydrolase (Ephx);
reduction: aldo-keto reductase (Akr), quinone oxidoreductase (Nqo), dihydropyrimidine
dehydrogenase (Dpyd); and oxidation: alcohol dehydrogenase (Adh), aldehyde dehydrogenase
(Aldh), flavin monooxygenases (Fmo), molybdenum hydroxylase (Aox and Xdh), cytochrome
P450 (P450), and cytochrome P450 oxidoreductase (Por). Two rapidly increasing stages of total
Phase-I gene expression after birth reflect functional transition of liver during development.
Diverse expression patterns were identified and some large gene families contained the mRNAs
of genes that are enriched at different stages of development. In conclusion, this study has
revealed the mRNA abundance of Phase-I genes in mouse liver during development and
provided a valuable foundation for mechanistic studies in the future.
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4.2 Introduction
Drug-metabolizing enzymes play a central role in the elimination of drugs from the body.
The metabolic reactions of hydrolysis, reduction, and oxidation usually introduce a small
functional group to the substrate or convert an existing functional group to a new group that may
be further conjugated with a large and bulky water-soluble co-substrate. The reactions
associated with hydrolysis, reduction, and oxidation are often called Phase-I reactions, and the
reactions associated with conjugation are often referred as Phase-II reactions.
Non-P450 Oxidative Enzymes
The oxidation of alcohols to aldehydes and carboxylic acids is sequentially catalyzed by
alcohol dehydrogenase and aldehyde dehydrogenase. ADHs are a group of zinc-containing,
cytosolic enzymes that facilitate the interconversion between alcohols and aldehydes (or
ketones) with the reduction of NAD+ to NADH, or oxidation of NADH to NAD+. In humans, ADH
isozymes in family 1 are responsible for the oxidation of ethanol and other small, aliphatic
alcohols, whereas ADH4 preferentially oxidizes large aliphatic and aromatic alcohols. The
substrates for ADH5 are preferentially long-chain alcohols, aromatic alcohols and also include
formaldehyde. The function of ADH6 is not clear, and ADH7 is not expressed in adult human
liver. Different families of ALDHs have different subcellular locations, and the ALDHs that are
responsible for oxidizing simple aldehyde, such as the metabolite of ethanol, are mitochondrial
enzymes.
Molybdozymes are flavoprotein enzymes consisting of two ∼150 kDa subunits, each of
which contains FAD, molybdenum, and two iron–sulfur (Fe2S2) centers. There are two major
molybdozymes that participate in the biotransformation of xenobiotics: aldehyde oxidase and
xanthine oxidoreductase. In contrast to P450s, which generally catalyze the oxidation of carbon
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atoms with a high electron density, AOX and XDH catalyze the oxidation of electron-deficient
carbons (i.e., double-bonded carbon atoms in nitrogen heterocycles). XDH contributes
significantly to the first-pass elimination of several purine derivatives (e.g., 6-mercaptopurine
and 2, 6-dithiopurine), and limits the therapeutic effects of these cancer chemotherapeutic
agents. Physiologically, XDH catalyzes the sequential oxidation of hypoxanthine to xanthine and
uric acid. A rare genetic disorder in XDH can cause xanthinuria, with the accumulation of
xanthine. AOX plays an important physiological role in the catabolism of biogenic amines and
catecholamines. Molybdozymes are located in the cytosol, and they transfer electrons to
molecular oxygen, which can generate reactive oxygen species and lead to oxidative stress and
lipid peroxidation.
Flavin-containing monooxygenases are a group of enzymes that catalyze chemical
reactions via the bound cofactor flavin. These reactions involve oxidation of heteroatoms,
particularly nucleophilic atoms such as the nitrogen of amines and the sulfur of thiols. FMOs and
P450s have several properties in common. They are both micorosomal enzymes that require
NADPH and O2, and many of the reactions catalyzed by FMOs can also be catalyzed by P450s.
To distinguish FMO and P450 in vitro, it has been noticed that FMOs are more heat labile and
catalyze reaction at optimum pH (8-10) higher than that for most P450 (pH 7-8). The regulatory
controls for FMOs in liver microsomes are different from P450s. Phenobarbital treatment is
found to suppress FMO1 expression in rats while it induces P450s. Additionally, the AhR
agonist TCDD induces FMO2 and FMO3 mRNA levels in mice (Tijet et al., 2006). Several other
oxidative Phase-I enzymes are also involved in the biotransformation of xenobiotics, such as
amine oxidases in brain and peroxidases in white blood cells, but they are either not expressed
or not functionally critical in liver, so are not discussed in this thesis.
Phase-I Enzymes in Reduction
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A variety of xenobiotics contain a carbonyl function (R-CHO and R1-CO-R2) that undergoes
reduction in vivo, which is generally catalyzed by NAD(P)H-dependent reductases that belong to
one of two superfamilies, the aldo-keto reductases and the short-chain dehydrogenases/
reductases (SDRs). The cytosolic and microsomal carbonyl reductase of SDRs in human play a
role in the reduction of carbonyl-containing xenobiotics. The AKRs are a superfamily of cytosolic
enzymes that reduce both xenobiotic and endobiotic compounds. Various members of the AKR
family have been implicated in the reduction of carbonyl-containing xenobiotics, such as
acetohexamide, befunolol, haloperidol and numerous aromatic and aliphatic aldehydes
(Rosemond and Walsh, 2004). AKR7A is one of the AKRs induced by Nrf2 following oxidative
stress, exposure to electrophiles, or depletion of glutathione. The AKRs mainly function in
reduction, but may also have a role as oxidizing enzymes in dihydrodiol dehydrogenation
(Burczynski and Penning, 2000).
Quinone oxidoreductases are cytosolic flavoproteins catalyzing the reduction of quinones to
hydroquinones. There are two closely related NQOs in human, NQO1 and NQO2, which have
different substrate specificities, and can be distinguished on their differential inhibition by
dicoumarol and quercetin, respectively. When quinones undergo one-electron reduction by POR
to semiquinone radicals, the reactive metabolites can cause oxidative stress by reacting with
oxygen to form reactive oxygen species and lead to damage to proteins and DNA through
alkylation (Bolton et al., 2000). In contrast, the two-electron reduction of quinones by NQOs
produces hydroquinones, which are usually stable enough to undergo glucuronidation or
sulfonation. The role of NQOs as a protective antioxidant or a pro-oxidant activator depends on
the properties of the resultant hydroquinone, which may undergo one-electron oxidation to form
the reactive semiquinone. This has been the mechanism of certain anticancer agents like
mitomycin C, because NQO1 is often overexpressed in tumor cells. Antioxidant response
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element and xenobiotic response element have been found in the regulatory region of NQO1,
which can be induced through AhR activation.
Dihydropyrimidine dehydrogenase is an NADPH-requiring homodimeric protein located
mainly in liver cytosol, where it catalyzes the reduction of anticancer drug 5-fluorouracil and
related pyrimidines. One metabolite of the antiviral Sorivudine can covalently bind to DPYD and
irreversibly inactivate the enzyme. Therefore, co-administration of 5-fluorouracil with Sorivudine
may increase the blood concentration of 5-fluorouracil to toxic or even lethal levels (Kanamitsu
et al., 2000). Several genetic polymorphisms also result in a partial or complete loss of DPYD
activity, and assessing an individual’s DPYD genotype (DNA sequence) or phenotype (DPYD
activity in peripheral blood cells) is recommended before 5-fluorouracil therapy to adjust the
dosage on an individual basis.
Phase-I Enzymes in Hydrolysis
The hydrolysis of xenobiotic esters and amides in humans is largely catalyzed by two
carboxylesterases called CES1 and CES2, both highly expressed in the liver and mainly
associated with the endoplasmic reticulum. CES1 generally catalyzes the hydrolysis of
xenobiotics with a small alcoholic leaving group (as in the case of delapril), while CES2
generally catalyzes the hydrolysis of xenobiotics with a small acidic or large alcoholic leaving
group (as in the case of procaine), although there are also overlapping substrates for both
enzymes. The hydrolysis of irinotecan by CES2 produces the active agent SN-38, which is
responsible the anticancer and toxic effects of irinotecan. High levels of CES2 in the intestine
are, at least in part, causing SN-38 generation and diarrhea after irinotecan treatment (Satoh et
al., 2002). In addition to hydrolyzing xenobiotics, CES hydrolyze numerous endogenous
compounds, such as palmitol-CoA, retinyl ester, platelet-activating factor and other esterified
lipids.
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Paraoxonases catalyze the hydrolysis of a broad range of organophosphates,
organophosphinites, aromatic carboxylic acid esters, cyclic carbonates, and lactones. Both
humans and mice express three paraoxonases, namely PON1, PON2 and PON3. PON1 and
PON3 are present in liver microsomes and plasma, while PON2 is expressed in several tissues
but not present in plasma. Plasma PON1 has been suggested to protect against atherosclerosis
by hydrolyzing specific derivatives of oxidized cholesterol or phospholipids in atherosclerotic
lesions. And PON1 knockout mice are predisposed to atherogenesis (Draganov and La Du,
2004). In addition to differences in tissue distribution, PONs in mice respond differently to
oxidative stress, in which PON1 is decreased, PON3 is increased and PON2 is not affected.
Epoxide hydrolases are found in the microsomal fraction of virtually all tissues, catalyzing
the trans-addition of water to alkene epoxides and arene oxides, which can form during P450dependent oxidation of aliphatic alkenes and aromatic hydrocarbons, respectively. EPHXs play
an important role in detoxifying electrophilic epoxides that might otherwise bind to proteins and
nucleic acids and cause cellular toxicity and genetic mutations, and they are normally distributed
parallel with P450s in tissues to presumably ensure the rapid detoxification of epoxides
generated in oxidative metabolism. The potentially toxic metabolites are converted to the
corresponding dihydrodiols, which are usually less reactive and easier to excrete. In mammals,
two forms of EPHX are mainly involved in hydrolyzing xenobiotics, the microsomal epoxide
hydrolase encoded by Ephx1 and the soluble epoxide hydrolase encoded by Ephx2. In rodents,
EPHX1 is under regulatory control by PPARα and inducible following peroxisome proliferator
treatment, whereas EPHX2 is inducible by Nrf2 in response to oxidative stress.
Many prodrugs are designed to be hydrolyzed by hydrolytic enzymes to release the active
drug. Enzymes with such function also include cholinesterase (e.g., for propranolol ester) and
alkaline phosphatase (e.g., for fosphenyoin). With the development of recombinant DNA
technology, numerous peptides, such as peptide hormones and monoclonal antibodies, have
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been used as therapeutic agents. And the activity of peptidases is having more and more
clinical implications in metabolizing these drugs.
Liver is the major organ for Phase-I drug metabolism, but before birth, the liver functions as
a hematopoietic organ. A functional transition occurs in liver after birth, and most of the drugmetabolizing enzymes mature during this period. Changes in expression of some Phase-I
enzymes during liver maturation in humans have been reported, including P450s (Stevens et al.,
2003; Koukouritaki et al., 2004; Stevens et al., 2008; Croom et al., 2009), CES (Yang et al.,
2009; Zhu et al., 2009), PON (Cole et al., 2003; Huen et al., 2009), ADH (Smith et al., 1971),
and FMO (Cherrington et al., 1998; Koukouritaki et al., 2002; Hines, 2006). The dynamic
changes in the ontogenic expression of these genes are thought to be responsible for the
substantial pharmacokinetic differences between newborns and adults, and this contributes to
differences in therapeutic efficacy and adverse drug reactions in pediatric patients (Kearns et al.,
2003; Blake et al., 2005; Hines, 2007; Hines, 2008; Hines, 2013). An in-depth understanding of
the regulatory mechanisms of the ontogeny of Phase-I enzymes is needed for safer and more
effective drug therapy for pediatric patients.
Several limitations exist in studies of the developmental regulation of Phase-I enzymes with
human samples. The first limitation is the ethical and technical issues in recruiting human
subjects and obtaining suitable human samples (Rowell and Zlotkin, 1997). Secondly, variations
in human metabolic capacity, which may be caused by genetic or environmental factors, can
interfere with studies aimed to reveal the regulatory mechanisms that are only due to age.
Furthermore, mechanistic loss-of-function or gain-of-function strategies are not applicable
directly in human samples. Animal models are advantageous in overcoming these limitations. In
recent years, mice and rats have surpassed other laboratory animals as the experimental
models of choice for the study of physiology, metabolism, and disease (Muruganandan and
Sinal, 2008; Hrycay and Bandiera, 2009). Advantages of these models include rapid growth,
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easy maintenance, and the development of genetic manipulation techniques for mechanistic
studies with gain-of-function and loss-of-function strategies. Several laboratories, including us,
have examined the ontogenic gene expression profiles in mouse or rat liver for some Phase-I
genes, including P450s (Hart et al., 2009; Cui et al., 2012c), Ces (Zhu et al., 2009), Akr (PrattHyatt et al., 2013), Adh and Aldh (Smolen et al., 1990; Alnouti and Klaassen, 2008), Pon (Li et
al., 1997), and Fmo (Falls et al., 1995; Cherrington et al., 1998; Janmohamed et al., 2004).
Developmental expression patterns of some Phase-I genes in mice and rats are similar to those
in humans.
Previous studies quantified Phase-I gene expression on the mRNA level by either Northern
blot, RT-PCR, microarrays, or multiplex suspension bead arrays, which only provide relative
quantification of a given gene and don’t allow a quantitative comparison of genes in different
families. With the development of next-generation sequencing technologies, such as RNA
sequencing (RNA-Seq), it is possible to define a whole transcriptome with low background noise,
no upper limit for quantification, and a high degree of reproducibility for both technical and
biological replicates (Mortazavi et al., 2008; Nagalakshmi et al., 2008). More importantly, RNASeq quantifies the true abundance of mRNA molecules in biological samples and enables
comparison of the expression of all genes (Malone and Oliver, 2011). We have reported RNASeq to reveal ontogenic patterns of P450s (Peng et al., 2012), phase-II enzymes (Lu et al.,
2013), transporters (Cui et al., 2012b), and epigenetic modifiers (Lu et al., 2012) in mouse liver
during maturation.
In this report, RNA-Seq was used to systematically quantify the mRNA expression of major
non-P450 Phase-I genes in mouse liver during postnatal maturation to define the ontogenic
profiles of these mRNAs. The groups included enzymes catalyzing reactions in hydrolysis
(carboxylesterase, paraoxonase, and epoxide hydrolase), reduction (aldo-keto reductase,
quinone oxidoreductase, and dihydropyrimidine dehydrogenase), and oxidation (alcohol
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dehydrogenase, aldehyde dehydrogenase, flavin monooxygenases, molybdenum hydroxylase,
and cytochrome P450 oxidoreductase). The purpose of this study was to generate
comprehensive information on the ontogeny of mRNAs of Phase-I genes in livers of mice, which
will form the foundation for determining the regulatory mechanisms controlling the various
transcription patterns of Phase-I genes during liver maturation.

4.3 Material and Methods
Animals, Total RNA Extraction, Sequencing Library Construction, RNA-Seq and RNA-Seq
data analysis
The source and breeding of animals, RNA extraction, library construction, RNA-Seq,
FASTQ data file collection and RNA-Seq data analysis were the same as those in Chapter 3.
Data Visualization and Statistics
The significance of the observed expression (measured FPKM) of a gene at a given age
relative to null expression (zero FPKM) was determined by the drop-in-deviance F test of the
fitted FPKM values to a Poisson log linear regression model with a zero intercept that permits
extra Poisson variation. The resulting p-values were adjusted for multiple-hypothesis testing by
the Benjamini-Hochberg method (FDR-BH; (Benjamini and Hochberg, 1995)). Phase-I drug
metabolizing enzymes that were significantly expressed (FDR-BH ≤ 0.05) in at least one of the
12 time-points were selected for analysis. Genes that were significantly differentially expressed
between at least two time points during liver development were determined by the drop-indeviance F test of the fitted FPKM values to a full (
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variation. The resulting p-values were adjusted for false discovery as before and those genes
with a FDR-BH ≤ 0.05 were considered significantly differentially expressed over time. Two-way
hierarchical clustering dendrograms were generated by JMP (version 10; SAS Institute, Inc.,
Cary, NC) to determine the expression patterns of the Phase-I genes during liver development.

4.4 Results
Total Expression and Proportions of Individual Phase-I Families during Liver maturation
Transcript abundances of the 186 mouse Phase-I genes were calculated by Cufflinks and
presented as FPKM values. If the Benjamini-Hochberg adjusted p value of the drop-in-deviance
F test (FDR-BH) for gene expression in at least one of the 12 ages was less than 0.05 for a
Phase-I gene, then that gene was considered to be expressed in liver during maturation. Table
4.1 lists the number of genes in each category that are significantly expressed at various
developmental stages of prenatal (day -2), neonatal (day 5), adolescence (day 25), and adult
(day 60) as well as the total number of genes expressed during liver development (Day -2 to
Day 60) in each Phase-I family. Of the 186 mouse Phase-I genes, 136 genes were expressed in
liver during maturation, but only about half of them (64) were expressed in prenatal liver. A
significant change in expression of Phase-I enzyme genes was observed around birth. The
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Table 4.1 Number of expressed genes in each Phase-I family in mouse liver at a
specific age of prenatal (day -2), Neonatal (day 5), adolescence (day 25), and adult (day
60), as well as during development (Day -2 to Day 60)

Prenatal
Day -2

Neonatal
Day 5

Adolescence
Day 25

Adult
Day 60

Liver
Day -2 to Day 60

Ces (18)

4

11

13

11

14

Pon (3)

2

3

3

3

3

Ephx (4)

2

2

2

2

2

Akr (16)

9

14

12

10

14

Nqo (2)

2

2

2

2

2

Dpyd (1)

0

1

0

1

1

Adh (6)

2

3

3

3

5

Aldh (20)

13

15

14

13

15

Aox+Xdh (5)

0

2

3

3

3

Fmo (7)

3

3

2

2

5

P450 (103)

26

55

59

50

71

Por (1)

1

1

1

1

1

64

112

114

101

136

Oxidation

Reduction

Hydrolysis

Gene Family

Total (186)

Numbers in the brackets represent total number of genes in the family
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number of the expressed genes increased to 112 in neonatal liver at day 5. The total expression
levels of all Phase-I mRNAs represented as cumulative FPKM values increased approximately
15 fold during postnatal liver maturation from day -2 (FPKM = 1,383) to day 60 (21,285) with two
surges (Fig. 4.1A), the first of which with six fold increase from day -2 (1,383) to day 1 (8,736)
and the other with 1.8 fold increase from day 10 (10,511) to day 20 (18,482), with each surge
followed by a relatively stable value of cumulative FPKM. Fig. 4.1B shows the composition of
the Phase-I families represented as percentages of the total FPKM value for each stage at
prenatal (day -2), neonatal (day 5), adolescence (day 25), and adult (day 60). The major PhaseI families expressed in prenatal liver were P450 (35%), Aldh (25%), Akr (21%), and Adh (10%)
are. After birth, there is a further increase in the relative proportions of the mRNAs of the P450s
(from 35% prenatal levels to about 60% after birth), and other highly expressed Phase-I families
include Ces, Adh, and Aldh.
Ontogeny of Genes of Phase-I Enzymes Involved in Hydrolysis Reactions
Carboxylesterases: CESs are enzymes that participate in the hydrolysis and transesterification of a variety of esters and amides. Five families of Ces genes are annotated in the
NCBI reference sequence database for mice. mRNA expression of four families of Ces (Ces1Ces4) was detected in mouse liver samples. The most abundant family in adult liver was Ces1,
and it consisted up to 58% of the total liver Ces mRNAs at age day 60 (Fig. 4.2A). Within the
Ces family 1, Ces1c had much higher expression than other members at postnatal ages. The
mRNA levels of Ces1 genes generally increased with age, but Ces1c and Ces1g showed a
peak of expression around day 20 and day 25 respectively (Fig. 4.2B). The Ces2 family was
moderately expressed, with Ces2a and Ces2e being the major members. The expression of
Ces2a gradually increased after birth till day 60, and Ces2e reached its adult levels at around
day 25 (Fig. 4.2C). The Ces3 family was also highly expressed in adult liver. Ces3a and -3b
exhibited similar developmental patterns with a rapid increase in expression between day 20
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Fig. 4.1
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Fig. 4.1 Total Expression and Proportions of Individual Phase-I Families during Liver
maturation.
(A) Total mRNA levels of the 186 mouse Phase-I genes in liver during postnatal maturation.
RNA-Seq was done for liver mRNAs of male C57BL/6 mice at 12 ages from 2 day before birth
to 60 days after birth. The FPKM values of all 186 Phase-I genes at each age were added and
plotted to show the developmental pattern of total Phase-I mRNAs. Bars represented the mean
± S.E.M. of three individual animals. (B) Percentages of FPKM values of each Phase-I family in
prenatal (day -2), neonatal (day 5), adolescence (day 25), and adult (day 60) livers.
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and day 30 (Fig. 4.2D). Ces4 family was expressed at a low level in liver, and it did not show
significant difference in expression during development. In total, 13 Ces genes had significant
changes in expression during development. A two-way hierarchical clustering analysis revealed
that the mRNAs of these Ces were all low in pre- and neonatal ages, but markedly increased to
adult levels around 20-30 days after birth (Fig. 4.2E).
Paraoxonases: PON function in hydrolyzing a broad range of organophosphates,
organophosphinites, aromatic carboxylic acid esters, cyclic carbonates, and lactones (Parkinson
and Ogilvie, 2008). Mouse livers expressed all three Pons with Pon1 being the most abundant
form. Hepatic expression of Pon1 increased with age to a peak level around day 20 and then
modestly decreased thereafter (Fig. 4.3A). At the prenatal age day -2, Pon2 mRNA level was
higher than Pon1 and Pon3. After birth, the Pon2 mRNA expression first increased till day 5
then decreased till day 25, and then went up again to reach adult level at day 60. Pon3 had
overall increased expressions after birth with small fluctuations at adolescent ages (Fig. 4.3B).
Epoxide Hydrolases: Ephxs are important in hydrolyzing and detoxifying electrophilic
epoxides, which may otherwise cause cellular and genetic toxicity through binding to proteins
and nucleic acids. Ephx1 and Ephx2 were the microsomal and soluble forms of these enzymes,
respectively. Ephx2 had a higher expression at mRNA level than Ephx1, and they exhibited
similar ontogenic patterns, with a sharp increase around birth, followed by a slight decrease
through at least day 10, and then a gradual increase till adulthood (Fig. 4.4).
Ontogeny of Genes of Phase-I Enzymes Involved in Reduction Reactions
Aldo-keto reductases: AKRs are a group of cytosolic enzymes that catalyze the reduction of
aldehydes and ketones to primary and secondary alcohols, respectively (Jin and Penning, 2007).
Mouse Akr genes consist of two families, Akr1 and Akr7, with a total of 16 genes. Akr1 is the
larger family with 5 subfamilies (Akr1a-e) and 15 genes. The RNA-Seq data showed 14 out of
the 16 mouse Akr genes were significantly expressed during liver maturation, and all the
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Fig. 4.2
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Fig. 4.2 Expression of Ces mRNAs during Liver Development in Male C57BL/6 Mice.
(A) mRNA proportion of each Ces family at age of day 60. (B) Expression profiles of Ces1 gene
family; (C) Expression profiles of Ces1 gene family without Ces1c; (D) Expression profiles of
Ces2 gene family; (E) Expression profiles of Ces3 and Ces4 gene families. Data are expressed
as mean FPKM and SEM of three individual animals. (F) Hierarchical clustering of expression
profiles for 13 differentially expressed Ces genes. The two trees describe the relationship
between different gene expression profiles (right tree) and various ages (bottom tree). The
dendrogram scale represents the correlation distances. Average FPKM values of three
replicates per age are given by colored squares: red, relatively high expression; blue, relatively
low expression. The dashed line categorizes the expression profiles into two major groups.
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Fig. 4.3

Fig. 4.3 Expression of Pon Genes during Liver Development.
(A) All three Pon ontogenic mRNA expression patterns; (B) Pon1 was removed to enlarge Pon2
and Pon3 expression patterns. Data are expressed as mean FPKM and SEM of three individual
animals.
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Fig. 4.4

Fig. 4.4 Expression Patterns of Ephx1 and Ephx2 during Liver Development.
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expressed Akrs exhibited significant differential expressions across the ages. The cumulative
FPKM values of all expressed Akr mRNAs increased 2-3 fold during postnatal liver development
(Fig. 4.5A). The composition of Akr mRNAs also changed with age, evidenced by alterations in
individual Akr genes. At day -2, Akr1a4 was the most abundant member, which accounted for
65% of the total Akr mRNAs. After birth, Akr1a4 mRNA slightly increased, but its proportion in
Akr mRNAs decreased (Fig. 4.5B-C). Akr1b7 was highest during the neonatal stage. It
accounted for 28% of the total Akr mRNA at day 1, but was undetectable after day 20. Akr1c6
was one of the major Akr genes in liver. It was lowly expressed at birth, gradually increased to a
peak at day 30, and then slightly decreased to adult levels around day 45. The mRNA
expression profile of Akr7a5 was similar to the profile of total Akr mRNAs, so the percentage of
Akr7a5 mRNA was relatively constant during development (10~15 %) (Fig. 4.5B-C). Two-way
hierarchical clustering analysis of the differentially expressed Akrs revealed two major patterns
(Fig. 4.5D). Unlike Ces genes, which all had low expression at the neonatal stage, some Akr
genes displayed neonatal enriched expression (Group 1). In Group 2, Akr genes however
showed relatively low expression during the neonatal ages. These genes were a diverse group
with some genes enriched at the adolescent stage (e.g. Akr1c20) and some at the adult stage
(e.g. Akr1c12).
Quinone oxidoreductase: NQO1 and NQO2 perform two-electron reduction of quinones to
hydroquinones. The RNA-Seq results demonstrated that the expression of Nqo1 was relatively
stable during development, with two small drops around birth and day 25. Nqo2 mRNA was
expressed higher than Nqo1 in mouse liver 5 days after birth. Nqo2 showed two periods of
increased expression during development; one from day 0 to day 15, and the other from day 30
to day 60 (Fig. 4.6A).
Dihydropyrimidine dehydrogenase: DPYD is located mainly in liver cytosol. It catalyzes the
reduction of 5-fluorouracil and related pyrimidines (Parkinson and Ogilvie, 2008). The mRNA
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Fig. 4.5
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Fig. 4.5 Expression Patterns of Akr Genes during Liver Development.
(A) Total mRNA profile of Akr genes in liver during development. The FPKM values of the 14
significantly expressed Akr genes are summed and plotted to show the developmental pattern
of total Akr mRNAs. (B) Individual Akr mRNAs (shown as percentages of total Akr mRNAs) at 2
days before birth and 1, 10, 20, and 60 days after birth. Each gene is presented in a unique
color for all ages. Only genes with mRNAs expressed at more than 1% at each age are listed,
and the rest are grouped as “Others”. (C) Expression profile of the 4 highly expressed Akrs (>10%
in B) in liver during development. (D) Hierarchical clustering of expression profiles for the 14
differentially expressed Akr genes. The dendrogram scale represents the correlation distances.
Average FPKM values of three replicates per age are given by colored squares: red, relatively
high expression; blue, relatively low expression. The dashed line categorizes the expression
profiles into two major groups.
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Fig. 4.6

Fig. 4.6 Expression Patterns of Nqo and Dpyd Genes during Liver Development.
(A) mRNA expression profile of Nqo gene in the liver during development. (B) mRNA
expression profile of Dpyd in the liver during development.
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expression of Dpyd showed a marked increase at day 1, dropped slightly till day 3, and then
went up gradually to adult levels at day 60, with a small plateau between day 20 and day 30 (Fig.
4.6B). The adult mRNA level of Dpyd was about 30 times higher than newborns.
Ontogeny of Genes of Phase-I Enzymes Involved in Oxidation Reactions
Alcohol dehydrogenases: ADHs metabolize a wide spectrum of substrates, including
ethanol, retinol, other aliphatic alcohols, hydroxysteroids, and lipid peroxidation products
(Duester et al., 1999). Five families of Adh genes exist in the mouse genome, and each family
consists of only one member that is significantly expressed during liver development. Adh1
mRNA was the most highly expressed, consisting of over 90% of Adh mRNAs in adult liver (Fig.
4.7), followed by Adh5 and then Adh4. Adh6 and Adh7 were minimally expressed in liver. Adhs
generally had lower expression at younger ages and reached stable mature levels at day 30 or
earlier. Adh1 and Adh5 also showed a peak of expression around day 0 or day 1 (Fig. 4.7).
Aldehyde dehydrogenase: ALDHs are a group of enzymes that catalyze the oxidation and
detoxification of aldehydes. There were total 20 Aldh genes in mouse genome, and 15 of these
genes were significantly expressed at mRNA levels during liver maturation. Of these 15 genes,
14 showed differential expression across the ages. The total mRNA of Aldh genes increased
almost linearly over fivefold from 2 days before birth to 60 days after birth (Fig. 4.8A). Aldh1l1
and Aldh2 were the major Aldh genes expressed at all ages of liver development. Aldh1b1,
Aldh4a1and Aldh9a1 accounted for a high percentage of total Aldh mRNAs at the prenatal and
adolescent stages, whereas Aldh1a1 matured later and became highly expressed only at the
adult stage (Fig. 4.8B). Two-way hierarchical clustering analysis of the differentially expressed
Aldhs also demonstrated diverse ontogenic patterns of individual Aldhs. Similar to Akrs, Group 1
Aldh genes had enriched expression at the perinatal stage, and genes in Group 2 were
expressed higher at the adult stage than at the perinatal stage (Fig. 4.8C).
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Fig. 4.7

Fig. 4.7 Expression Patterns of Adh Genes during Liver Development.
(A) Total mRNA profile of all five Adh genes during liver development. (B) Ontogenic mRNA
expression patterns of individual Adh gene; (C) Adh1 is removed to enlarge Adh4 and Adh5
expression patterns; (D) Adh4 and Adh5 are removed to enlarge Adh6-ps1 and Adh7
expression patterns.
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Fig. 4.8
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Fig. 4.8 Expression Patterns of Aldh Genes during Liver Development.
(A) Total mRNA profile of Aldh genes in liver during development. The FPKM values of the 15
significantly expressed Aldh genes are summed and plotted to show the developmental pattern
of total Aldh mRNAs. (B) Individual Aldh mRNAs (shown as percentages of total Aldh mRNAs)
at 2 days before birth and 1, 10, 20, and 60 days after birth. Each gene is presented in a unique
color for all ages. Only genes with mRNAs expressed at more than 1% at each age are listed,
and the rest are grouped as “Others”. (C) Hierarchical clustering of expression profiles for the 14
differentially expressed Aldh genes. The dendrogram scale represents the correlation distances.
Average FPKM values of three replicates per age are given by colored squares: red, relatively
high expression; blue, relatively low expression. The dashed line categorizes the expression
profiles into two major groups.
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Flavin monooxygenases: Like P450s, FMOs are microsomal enzymes that require NADPH
and O2. They oxidize a variety of xenobiotics, including the nucleophilic nitrogen, sulfur, and
phosphorus heteroatom (Parkinson and Ogilvie, 2008). Five families of Fmos are annotated in
the mouse genome. The mRNA expression of Fmo5 increased gradually with age, and was the
most abundant in adult males, followed by Fmo1, which showed a rapid increase of expression
from birth to day 5, and then slightly increased to a peak at day 25 and decreased to adult
expression levels at day 30. The expression of Fmo3 became detectable at 10 days after birth,
increased to peak levels at day 25, and then dropped to negligible levels after day 30 in male
mice (Fig. 4.9A). Fmo2 and Fmo4 were very lowly expressed in liver during maturation, and
Fmo2 was mainly detected at the adolescent stage from day 10 to day 20 (Fig. 4.9B).
Molybdenum hydroxylases: Mammalian molybdenum hydroxylases require FAD and
molybdenum cofactor for their catalytic activity. There are two major molybdenum hydroxylases
participating in the metabolism of xenobiotics: aldehyde oxidases (AOX) and xanthine
oxidoreductase (XDH) (Parkinson and Ogilvie, 2008). Four Aox genes are annotated in the
mouse genome and two of them were expressed during liver maturation. Aox3 was the major
Aox in mouse liver. Its mRNA level increased over 10 fold from day -2 to day 3, remained stable
from day 3 to day 25, and then went up about 5 fold to adult level at day 60. Aox1 was
expressed at lower level than Aox3, and also showed an increase of expression after day 25
(Fig.10A). Xdh mRNA expression gradually increased about 10 fold from day -2 to day 20, and
then remained relatively stable (Fig. 4.10B).
NADPH-cytochrome P450 oxidoreductase: POR transfers electrons from NADPH to
cytochrome P450s for their catalytic function. The expression of Por mRNA rose sharply around
birth, and decreased to about half the level of day 1 by day 5. From day 5 to day 20, Por
expression was relatively stable. Then at day 25, it decreased again to about half the level of
day 20 and remained at that level till maturity (Fig. 4.11).
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Fig. 4.9

Fig. 4.9 Expression of Fmo Genes during Liver Development.
(A) All five Fmo ontogenic mRNA expression patterns; (B) Fmo1,3,5 are removed to enlarge
Fmo2 and Fmo4 expression patterns.
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Fig. 4.10

Fig. 4.10 Expression of Molybdenum Hydroxylases during Liver Development.
(A) mRNA ontogenic patterns of aldehyde oxidase Aox1 and Aox3; (B) mRNA ontogenic
patterns of Xdh.
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Fig. 4.11

Fig. 4.11 mRNA Expression Pattern of Por during Liver Development.

106

4.5 Discussion
The current study provided a comprehensive quantitative analysis of the developmental
expression of major non-P450 Phase-I enzymes on mRNA levels in mouse liver by RNA-Seq,
including enzymes involved in hydrolysis, reduction, and oxidation. Compared with other
commonly used methods for mRNA quantification, such as microarray, branched DNA, and
real-time PCR, which detect mRNAs by probe hybridization and rely on hybridization specificity
and efficiency, RNA-seq directly counts sequence reads of the nucleotide molecules in
biological samples, thus it is able to quantify the mRNA expression with minimal bias. The
expression of a gene transcript is represented by FPKM, which normalized sequencing depths
between different samples and sizes between various genes, allowing direct comparison of
mRNA abundance among various transcripts on a genome-wide scale.
From perinatal through neonatal to adult liver, the total FPKM values of Phase-I mRNAs
increase 15 fold with two rapidly increasing stages (Fig. 4.1A), which may reflect functional
transition of liver from a hematopoietic organ to a metabolic organ during liver maturation. The
first surge occurs from 2 days before birth to 1 day after birth. During that period of time, the
total FPKM values increase 8 fold and the composition of each Phase-I family also changes
dramatically. P450s are the most changed Phase-I enzymes during this perinatal surge,
indicating an urgent need for liver to deal with exposure to xenobiotics immediately after birth.
The second surge occurs from day 10 to day 20 with a rapid increase in abundance of Phase-I
mRNAs. This period is also the most rapidly growing stage of postnatal liver maturation. After
day 25 (adolescence), the total FPKM levels and composition of the Phase-I enzymes are
consistent till day 60 (adult). These data indicate that during the developmental period from
neonatal to adolescence, hepatic expression of many Phase-I enzyme genes change
dramatically. Expectedly, the ability to metabolize xenobiotics including drugs by Phase-I
enzymes should also be changed dramatically in this period of time. Determination of the
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mechanisms in regulation of the Phase-I gene expression during this developmental period will
provide insight for understanding drug metabolism in pediatric patients.
The ontogenic patterns of many Phase-I genes we found in this study are consistent with
the previous findings in mice and humans by other researchers. For example, the high
expression of carboxylesterase 1 (Ces1) in our results was consistent with the literature that
Ces1 was the major expressed carboxylesterase gene in mouse liver (Holmes et al., 2010).
Another study demonstrated that the expression of mouse Ces1 and Ces2 in the liver were
markedly lower in newborns than in adults and increased gradually to levels of adult animals in
2 to 4 weeks (Zhu et al., 2009). Our data confirmed these, and provided more details on
changes with age and more information about individual members of each gene family (Fig. 4.2).
Adult humans also express higher levels of CES1 and CES2 than children and fetus (Yang et al.,
2009). As a former study suggested that the CES genes from mouse and human had
evolutionally conserved transcriptional regulatory mechanisms (Hosokawa et al., 2007), these
ontogeny data in mice are expected to provide important resources for interpreting the
developmental regulation of CESs in humans.
A study showed that lower levels of PON1 enzyme persisted in young children till at least 7
years of age (Huen et al., 2009), which was similar to the ontogenic pattern of Pon1 mRNA
expression in mice. Another group found that the plasma PON1 activity in mice reached a
plateau in 3 weeks after birth (Li et al., 1997), which is similar to our data of Pon1 mRNA
expression in mouse liver (Fig. 4.3). A transgenic mouse strain that lacks endogenous Pon1, but
with the human PON1 gene, exhibited a similar developmental pattern of expression as wildtype mice,

indicating conserved developmental regulatory elements between mouse and

human PON1 (Cole et al., 2003), making our data helpful for mechanistic studies.
Quinones are highly reactive molecules. They can undergo one-electron reduction,
commonly catalyzed by NADPH-cytochrome P450 reductase, and generate semiquinone
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radicals, which are reactive metabolites themselves and may cause oxidative stress by redox
cycling. The resultant reactive oxygen species can lead to DNA damage, lipid peroxidation,
membrane damage, cytotoxicity, and neoplasia. NQO1 and NQO2 compete for the above
reaction and catalyze the two-electron reductive metabolism of quinones to produce stable
hydroquinones, which are removed by glucuronidation or sulfonation (Long and Jaiswal, 2000;
Parkinson and Ogilvie, 2008). Quinones are ubiquitous in nature and human exposure to
quinones occurs through diet, airborne pollutants, and drugs (Monks and Jones, 2002).
Therefore, quinone oxidoreductase has a highly important role in developmental toxicology. The
present study is the first demonstration of the developmental expression of these genes. NQO1
and NQO2 are two closely related flavoproteins. Although they have overlapping substrate
specificities, significant differences exist in relative affinities for various substrates (Das et al.,
2006). Our results also revealed the differential expression of Nqo1 and Nqo2 mRNAs during
development (Fig. 4.6A). The changes of expression during liver maturation may have strong
toxicity impact in children. Further studies are needed to address the ontogeny of NQO
enzymes and their significance in human health.
Although FMO3 is the most highly expressed FMO family member in adult human liver, it
demonstrated gender-specific expression in mice, and was not detectable in male liver of mice
(Falls et al., 1995). Our data only examined mRNA expression in male animals and was
consistent with this result. Fmo3 was expressed equally in male and female mice, even at 4
weeks of age (Cherrington et al., 1998), and then after puberty, the gender difference appeared
due to sex steroids (Falls et al., 1997). We also showed the detailed time window when the
shutdown of Fmo3 happened, which was between day 25 and day 30 (Fig. 4.9A). Fmo1 in mice
showed increased expression after birth, unlike human, in which Fmo1 was most abundant in
fetal liver and absent after birth (Hines, 2006). Interestingly,

Fmo3 was not expressed

immediately after birth in mice, and appeared after 10 days of age, which is similar in humans
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(Hines and McCarver, 2002). Thus, neonatal mice may serve as a model to study the
mechanism of the delayed onset of FMO3 expression in humans.
AOX and XDH are important enzymes that catalyze the oxidation of electron-deficient
carbon atoms, often found in nitrogen heterocycles, such as purines and pyrimidines. These
typically complement oxidations by cytochrome P450s, which catalyze the oxidation of carbon
atoms with a high electron density. A broad range of xenobiotics are substrates for
molybdozymes, including immunosuppressive drugs like 6-mercaptopurine, antiviral drugs like
6-deoxyacyclovir, and antidepressant citalopram. They also perform important physiological
functions by metabolizing biogenic amines and catecholamines, and may be related to neuron
disease (Bendotti et al., 1997). The final electron acceptor of AOX and XDH is oxygen, so the
reactions can generate reactive oxygen species and lead to oxidative stress and lipid
peroxidation (Parkinson and Ogilvie, 2008). Although having critical roles in biotransformation,
the expression and regulation of molybdozymes are largely understudied, especially compared
to other drug metabolizing enzymes. Our first report on the developmental expression pattern of
these genes will facilitate drug metabolism and toxicity studies related to molybdozymes.
POR is the only electron donor for all microsomal P450s, and alteration in POR activity can
affect P450-catalyzed drug oxidation (Hart et al., 2008). Our previous study had revealed the
ontogenic mRNA expression of all P450s in mouse liver, and a large number of P450 genes had
increased expression after birth (Peng et al., 2012). Here we showed hepatic mRNA expression
of Por, which could influence P450 activities, actually decreased during postnatal development
(Fig. 4.11). Thus, the level of Por needs to be taken into considerations when we study the
developmental enzyme activity of P450s.
Protein levels and enzyme activities of Phase-I genes were not determined in this study due
to extensive workload and technical limitations. Specific antibodies, substrates and inhibitors for
many individual mouse Phase-I enzymes are not available. Yet compared with the few studies
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that measured protein expression or enzyme activities of certain Phase-I genes in mouse liver
during development, such as CES (Zhu et al., 2009), PON (Cole et al., 2003), EPHX (Rouet et
al., 1984), and FMO (Cherrington et al., 1998), our mRNA expression patterns were fairly
indicative of the protein or enzyme activity levels. But whether the mRNA expression can be
extrapolated to the protein expression and enzymatic activity of the Phase-I enzymes remain to
be validated. For future studies, applying certain pediatric drugs to the mice of different
developmental stages and checking the pharmacokinetics of these drugs to see if the
metabolism pattern can be predicted by the current gene expression may be informative.
Technological breakthroughs in proteomics and metabolomics are essential to the study of
ontogeny of Phase-I enzymes on the protein contents and metabolite levels in the future.
In summary, the present study has provided the first knowledge regarding the true
quantification of the mRNA ontogenic patterns of all major known non-P450 Phase-I enzymes
during mouse liver development. Such knowledge will serve as a foundation for further
understanding the regulation of gene expression and physiological function of these enzymes in
liver during development and aid in a better understanding of the kinetics of xenobiotic
metabolism during perinatal and postnatal maturation.
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Chapter 5 : FXR in Regulation of Postnatal Liver Development and
Phase-I Gene Expressions

5.1 Abstract
The functions of liver, including the expression of Phase-I drug metabolizing enzymes, are
not mature at birth, and hepatic gene expressions change dramatically during liver maturation.
Farnesoid X receptor is critical for bile acid and lipid homeostasis in liver. However, the role of
FXR in regulating liver maturation and Phase-I drug metabolizing gene ontogeny is not clear.
Hence, we applied RNA sequencing to quantify the developmental transcriptome in both FXRnull and its control (C57BL/6) mouse livers during development, with a focus on Phase-I genes.
Liver samples of male C57BL/6 and FXR-null mice at 6 different ages from prenatal to adult
were used. Similarity analysis of global gene expression indicated that liver maturation was
delayed in FXR-null mice at adolescent stage. FXR knockout mice showed prolonged activation
of neonatal-specific pathways and delayed maturation of multiple metabolic pathways compared
to wild-type mice. Surprisingly, knockout of FXR induced heart, kidney and many other organ
developmental processes in liver. The loss of FXR also led to increased transcription of 90% of
the differentially expressed transcription regulators during liver maturation. Among the 185
Phase-I genes from 12 different families, 136 were expressed, and differential expression during
development occurred in genes from all 12 Phase-I families, including hydrolysis:
carboxylesterase (Ces), paraoxonase (Pon), epoxide hydrolase (Ephx); reduction: aldoketo
reductase (Akr), quinone oxidoreductase (Nqo), dihydropyrimidine dehydrogenase (Dpyd); and
oxidation:

alcohol

dehydrogenase

(Adh),

aldehyde

dehydrogenase

(Aldh),

flavin

monooxygenases (Fmo), molybdenum hydroxylase (Aox and Xdh), cytochrome P450 (P450),
and cytochrome P450 oxidoreductase (Por). The data also suggested new Phase-I genes
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potentially targeted by FXR. These results indicate an important role of FXR in regulation of liver
maturation and Phase-I genes ontogeny.

5.2 Introduction
The liver is the largest internal organ in the body, taking up about 2-4% of body weight in
humans. As part of the digestive system, a matured liver plays a major role in nutrient
homeostasis, including the synthesis, metabolism and transport of carbohydrates, proteins and
fats. Venous blood from the stomach and intestine flows through the liver by the portal vein
before entering systemic circulation. Thus liver is the first organ to encounter and deal with
ingested drugs, environmental toxicants and intestinal bacteria. Bioactivation, detoxification and
filtration of particulates in immune defense are also critical functions of the liver (Jaeschke,
2008). Whereas in utero, fetal liver is the major hematopoietic organ, generating blood cells,
and hematopoiesis is active in liver even shortly after birth (Takeuchi and Miyajima, 2006).
Definitive hematopoiesis requires a specific microenvironment in the organ. Therefore, from
birth to maturity, there are dramatic changes happen in liver to achieve the organ growth and
functional transition. And the differences between neonatal and adult livers have been
implicated in clinical issues. Disorders of iron metabolism such as hemochromatosis having
severe effects in neonates including fulminant liver failure may be due to the active
hematopoiesis in neonatal liver (Beath, 2003). Age-related sensitivity to drugs is at least partly
attributable to differences in hepatic metabolic activity (Pineiro-Carrero and Pineiro, 2004).
Phase-I drug metabolizing enzymes catalyze the oxidation, reduction and hydrolysis of
xenobiotics. A functional transition occurs in liver after birth, and most of the drug-metabolizing
enzymes mature during this period. Changes in expression of some Phase-I enzymes during
liver maturation in humans have been reported, including P450s (Stevens et al., 2003;
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Koukouritaki et al., 2004; Stevens et al., 2008; Croom et al., 2009), CES (Yang et al., 2009; Zhu
et al., 2009), PON (Cole et al., 2003; Huen et al., 2009), ADH (Smith et al., 1971), and FMO
(Cherrington et al., 1998; Koukouritaki et al., 2002; Hines, 2006). The dynamic changes in the
ontogenic expression of these genes are thought to be responsible for the substantial
pharmacokinetic differences between newborns and adults, and this contributes to differences
in therapeutic efficacy and adverse drug reactions in pediatric patients (Kearns et al., 2003;
Blake et al., 2005; Hines, 2007; Hines, 2008; Hines, 2013). An in-depth understanding of the
regulatory mechanisms of the ontogeny of Phase-I enzymes is needed for safer and more
effective drug therapy for pediatric patients.
The Farnesoid X receptor (FXR) is a bile acids-activated transcription factor and a member
of the nuclear receptor superfamily (Zhu et al., 2011). In the immediate neonatal period, bile
acids are required for the newborns to absorb milk. There is a surge of serum and liver bile
acids levels after birth (Cui et al., 2012a), so the increased activation of FXR immediately after
birth may be important for regulation of hepatic gene expression at early ages. Previous studies
have identified FXR as a key metabolic regulator. It is critical for bile acids, lipid and glucose
homeostasis (Sinal et al., 2000; Claudel et al., 2005), and even plays a role in liver regeneration
(Chen et al., 2011). Most of these liver functions regulated by FXR are established during
postnatal liver development, and disorders like fatty liver may have roots in the neonatal
period(Beath, 2003). Thus understanding the role of FXR in liver maturation may provide
important insights on liver physiology and diseases.
The role of FXR in regulating certain drug processing genes has been established. Bile
acids activate FXR in the intestine and liver, which induces the expression of PXR, facilitating
the detoxification of lithocholate and xenobiotics by inducing CYP3A, Phase-II enzymes (e.g.
sulfotransferase 2A1), and transporters (e.g. MRP2, MRP3) xenobiotics (Kliewer et al., 2002;
Jung et al., 2006). FXR also maintains bile acid homeostasis by feedback inhibition of
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expression of important genes in bile acid synthesis, for example, CYP7A1, which is the ratelimiting enzyme in the classic pathway of bile acid synthesis, and CYP8B1, which is required for
the synthesis of cholic acid. Functional FXR polymorphism is common (2.5-12%), and has been
associated with changes in FXR-target gene expression in humans (Marzolini et al., 2007;
Kovacs et al., 2008). Understanding the regulatory mechanism of FXR on hepatic expression of
drug processing genes in newborns will greatly help us to understand the natural and aberrant
development of drug processing genes in pediatric pharmacology.
In the current study, we used RNA-Sequencing to quantify the liver transcriptome during the
developmental period from perinatal stage to adult, in both wild-type and FXR knockout mice,
and focused on the analysis of Phase-I gene ontogeny. RNA-Seq allows the analysis of the
whole transcriptome with lower background noise, higher sensitivity, and a high degree of
reproducibility compared to traditional technologies (Mortazavi et al., 2008; Nagalakshmi et al.,
2008). More importantly, RNA-Seq quantifies the true abundance of RNA molecules in
biological samples and enables the comparison of expression of all genes in multiple samples
(Malone and Oliver, 2011). Our results revealed the significant differences in FXR-null livers
compared to control livers during postnatal development, and also suggested novel roles of
FXR in the regulation of liver maturation and Phase-I gene developmental expression.

5.3 Materials and Methods
Animals
We used C57BL/6 mice as the wild-type animals. The animal purchase, breeding and
tissue collection for wild-type mice were performed as previously described in Chapter 2.
Breeding pairs of Fxr-/- mice on C57BL/6 background were kindly provided by Dr. Grace Guo
from University of Kansas Medical Center. These knockout mice were bred under standard
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conditions in the Office of Animal Care Facility at the University of Connecticut. The use of these
mice was approved by the University of Connecticut's Institutional Animal Care and Use
Committee. Liver samples (n=3) from Fxr-/- mice were collected at the following 6 ages: day -2
(gestational day 17.5), day 1 (exactly 24 hours after birth), and days 5, 20, 25, and 60 (collected
at approximately 9:00 AM). These ages represent the periods of prenatal (day -2), neonatal
(days 1 and 5), juvenile (days 20 and 25), and young adult (day 60). Due to potential variations
caused by the estrous cycle in maturing female mice, only male livers were used in this study.
The livers were immediately frozen in liquid nitrogen after removal and stored at -80℃.
Total RNA Extraction, Sequencing Library Construction, and RNA-Seq
RNA extraction, library construction, RNA-Seq and FASTQ data file collection were
performed as previously described in Chapter 2.
RNA-Seq Data Analysis
For comparison of wild-type and FXR knockout samples at the 6 ages of day -2, 1, 5, 20, 25
and 60, the RNA-Seq reads from the FASTQ files of these two types of mice were mapped to
the mouse reference genome (GRCm38/mm10) by Tophat 2.0.8. The output files in BAM format
were analyzed by Cufflinks 2.1.1 to estimate the transcript abundance.
Gene Ontology Analysis
Statistically significant differential expression in this analysis were defined using the
following criteria 1) the gene mean FPKM>1 across the ages; 2) fold change for the average
FPKM of the three replicates >1.5 between compared samples; 3) Benjamini-Hochberg
adjusted p-values from t-test <0.05. Lists of differentially expressed genes at ages of day -2, 1,
5, 20 and 25 compared to day 60 in FXR knockout mice were supplied to High-Throughput
GoMiner for biological interpretation (Zeeberg et al., 2005). Significantly enriched GO categories
were selected with a FDR <0.05.
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Data Visualization and Statistics
ANOVA was used to test for significant difference in expression during development. Pvalues were adjusted using Benjamini-Hochberg algorithm with a threshold of 0.05. For Pearson
correlation coefficient-based heat map visualization, the average FPKM of the three replicates
at each age were used to calculate the Pearson’s r values between different ages. For the
visualization of nuclear receptors and core transcription factors expression in liver, significant
differential expressions were defined in the same way as in GO analysis. To study the distance
of Phase-I gene ontogenic pattern between WT and Fxr-/- samples, the average FPKM values
from three individual animals were used. For each gene, the FPKM values at the 12 ages (6
ages per genotype) were divided by the mean FPKM of the 12 ages before calculating distance
in order to normalize the difference of expression level among genes.

5.4 Results
Biological Interpretation of the Liver developmental Transcriptome in Fxr-/- Mice
To further understand the regulation of postnatal liver development, we quantified the
developmental transcriptome in nuclear receptor FXR knockout mice as well as wild-type mice
at the same ages of day -2, 1, 5, 20, 25 and 60. Our RNA-Seq data viewed in the genome
browser validated that there was no functional FXR mRNA generated in the knockout samples
(Fig. 5.1).
The similarity of gene expression at the 6 ages was analyzed in both wild-type and Fxr-/samples (Fig. 5.2). Consistent with Fig. 2.2, correlation heat map of only 6 ages also displayed
clear developmental stages (Fig. 5.2A). But the correlation heat map for Fxr-/- samples
exhibited dramatic differences in developmental stage transition (Fig. 5.2B). The outstanding
feature was that the difference between adolescent (day 20 and 25) and neonatal (day 1 and 5)
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Fig. 5.1

WT sample
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Fig. 5.1 RNA-Seq Validation of Fxr-/- Mouse Model.
IGV browser view shows that there are not sequencing reads mapped to the last exon of Fxr
gene, which is consistent with the animal model created by Sinal et al.
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Fig. 5.2

Fig. 5.2 Similarity of Gene Expression during Development in Wild-type (A) and Fxr-/(B) Mice.
Pearson correlation coefficient-based heat map are drawn to present the similarity of gene
expression profiles based on all expressed genes over 6 different ages.
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stages was diminished. The knockout of FXR seemed to delay the postnatal maturation of liver.
And the GO analysis further proved this.
At the ages of day 20 and 25 compared to day 60, there were a lot more differentially
expressed genes in Fxr-/- samples than in wild-type samples (Fig. 5.3A and 5.4A). The enriched
GO categories for over-expressed genes in Fxr-/- samples could generally be divided into two
groups (bracket B and C in Fig. 5.3A). One group was similar GO categories that showed up in
the analysis of wild-type samples, but they were not as age-specific as in wild-type and also
enriched at later ages in knockout samples (Fig. 5.3B). The other group contained GO
categories not appeared in wild-type samples, and they were mainly pathways for other organ
development instead of the liver (Fig. 5.3C). This result indicted that the nuclear receptor FXR
might have important roles to maintain the liver identity during postnatal development. The
enriched GO categories for under-expressed genes in Fxr-/- samples were similar to that in
wild-type samples, including all kinds of metabolic processes. But many of them showed
delayed maturation and were continually enriched at later ages. Examples were given in Fig.
5.4B.
Effects of FXR Knockout on the Expression of Hepatic Nuclear Receptors and Core
Transcription Factors
Previous studies on the regulation of liver-specific genes have identified a core group of
hepatic regulators, which form a complex and plastic hepatic transcription factor network during
liver development (Kyrmizi et al., 2006). To assess the role of FXR in this network and the effect
of FXR knockout on the expression of hepatic transcription regulators, we examined the
developmental expression of core transcription factors and all nuclear receptor family members
in livers of wild-type and Fxr-/- mice. A total of 53 genes were summarized into the transcription
regulator group (Table 5.1), 39 of them were expressed in liver during development (mean
FPKM>1), and 30 of them had significant differential expression between wild-type and Fxr-/120

Fig. 5.3
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Fig. 5.3

Fig. 5.3 Gene Ontology Analysis for Over-expressed Genes during Development
Compared to Day 60 in Fxr-/- Mice.
(A) Heat map for GO categories with significant gene over-expression at ages of day -2, 1, 5,
20 and 25. The color represents the false discovery rate of each GO category. The numbers on
the right are the cumulative number of GO categories. The brackets B and C are used to label
different groups of GO categories. Representative GO categories in each bracket are show in
the corresponding panels of (B) and (C). The FDR values with red color in panel (B) indicate
that the same GO category has a FDR>0.05 in age-matched wild-type samples.
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Fig. 5.4
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Fig. 5.4 Gene Ontology Analysis for Under-expressed Genes during Development
Compared to Day 60 in Fxr-/- Mice.
(A) Heat map for GO categories with significant gene under-expression at ages of day -2, 1, 5,
20 and 25. The color represents the false discovery rate of each GO category. The numbers on
the right are the cumulative number of GO categories. The bracket B is used to label a group of
GO categories. Representative GO categories in the bracket are show in panel (B). The FDR
values with red color in panel (B) indicate that the same GO category has a FDR>0.05 in agematched wild-type samples.
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Table 5.1 Expression summary of hepatic transcription regulator in wild-type and
Fxr-/- mice

Status

Genes

Count

Increased in Fxr-/- samples

Esr1, Rora, Nr3c2, Nr1d2, Onecut1, Thrb,
Nr6a1, Nr1i3, Rarb, Nr2c2, Rorc, Nr2f2, Foxa1,
Pparg, Rara, Nr5a2, Nr1h4, Foxa2, Nr3c1, 27
Hnf1a, Esrra, Ppard, Ppara, Nr1i2, Foxa3, Rxra,
Cebpa

Decreased in Fxr-/- samples

Nr0b2, Nr2c1, Nr1h3

3

Not
significantly
changed
Rxrg, Rarg, Hnf1b, Thra, Nr1d1, Rxrb, Nr1h2,
between wild-type and Fxr-/9
Nr2f6, Hnf4a
samples
Not expressed in liver

Nr2e1, Rorb, Nr0b1, Nr2e3, Esr2, Nr5a1, Nr4a3,
14
Nr4a2, Vdr, Hnf4g, Esrrb, Nr2f1, Esrrg, Nr4a1
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Fig. 5.5

Fig. 5.5 The Effect of Fxr-/- on Developmental Expression of Nuclear Receptors and
Core Transcription Factors in Liver.
Heat map of expression profiles are drawn for all nuclear receptors and main hepatic
transcription factors (genes labeled on the right) with significant differential expression between
wild-type and Fxr-/- samples. For each gene, the value of log2(1+[fold change to mean FPKM])
over the ages are calculated to show the trends of expression. The three gene names in red
color have higher expression in wild-type samples than in Fxr-/- samples.
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mice for at least one age during development (Fig. 5.5). Within the differentially expressed
genes, only 3 showed decreased expressions in the knockout samples, including Nr2c1, Nr1h3
and the known FXR target gene Nr0b2, and the rest 27 genes were all induced in the knockout
samples. The increased expression of most hepatic transcription regulators in Fxr-/- mice was
probably a result of compensatory effects for the loss of FXR, and suggested widespread
interactions within the transcription regulatory network where regulators cooperated in
determining the hepatic phenotype.
Phase-I Gene Ontogeny in Fxr-/- Mice
After examining the global effect of FXR knockout during liver development, we took a
further step to assess the ontogeny of individual Phase-I genes. Based on UCSC Genes Track
mm10, there were 185 Phase-I genes in the 12 major families of Phase-I genes, and our data
showed 136 of them were expressed during liver maturation in wild-type (WT) and Fxr-/- mice
(average FPKM >1). Differential expression between wild-type and knockout mice occurred in
genes from all 12 Phase-I gene families for at least one age during development, suggesting an
extensive role of FXR in gene regulation. The distances of developmental pattern between WT
and Fxr-/- samples were calculated and Phase-I genes were listed in the order from small to
large distance in Fig. 5.6. The genes at the upper part showed more difference in their
developmental expression patterns by the knockout of FXR, and the top 10 most altered genes
were Cyp26a1, Cyp4a12b, Cyp1a1, Adh6-ps1, Cyp2a4, Cyp7a1, Cyp2d13, Fmo2, Cyp2d37-ps,
and Akr1b7. Changes in expression of these genes showed developmental stage-specific
effects, for example, Cyp26a1 and Cyp4a12b were only strongly induced or repressed at day 60,
Cyp2a4 was induced at adolescent stage, and Akr1b7 was markedly repressed at neonatal
stage in the knockout mice compared with wild-type. Cyp3a11 is one of the most important
genes in drug metabolism. Research has shown that CYP3A11 expression was induced in the
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Fig. 5.6 Developmental Expression Patterns of Phase-I Genes in Livers of Wild-type
and Fxr-/- Mice.
Heat map of expression profiles are drawn for all expressed Phase-I genes (FPKM>1). And
genes are listed in an order based on the distance of ontogenic pattern between WT and Fxr-/samples, with the ones at the top showing patterns most altered by FXR knockout.
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Fig. 5.7
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Fig. 5.7 Expression Patterns of CYP3A11 during Liver Development.
Data are expressed as mean FPKM and SEM of three individual animals.
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absence of FXR (Schuetz et al., 2001). But in our results, induction of CYP3A11 mRNA only
happened at day 20, and Fxr-/- does not significantly alter CYP3A11 ontogenic trend (Fig. 5.7).
Developmental Expression of Known FXR Target Genes
As we have found out widespread changes of gene expression in FXR-null mice, especially
in those hepatic nuclear receptors and core transcription factors, it would be difficult for us to
conclude on the direct role of FXR in regulation of gene transcription. Therefore, we examined
the developmental expression pattern of several know FXR target genes. CYP7A1 is the ratelimiting enzyme in the classic bile acid synthesis pathway, and CYP8B1 is required for synthesis
of cholic acid. The known mechanisms of FXR in regulating CYP7A1 and CYP8B1 are as
follows. The activation of FXR by bile acids in the liver induces nuclear receptor SHP (Nr0b2),
which interacts with HNF4 and LRH-1 and blocks their activation of Cyp7a1 and Cyp8b1
transcription. On the other hand, activated FXR in the intestine can induce FGF-15 (FGF-19 in
human), which circulates to liver and bind FGFR4 to activate JNK phosphorylation pathway and
suppress Cyp7a1 and Cyp8b1 expression (Claudel et al., 2005). Our results demonstrated that
CYP7A1 mRNA level was significantly induced at all 6 ages in FXR knockout mice, and the
induction fold change was largest at day 20, indicating the repression of CYP7A1 by FXR was
more critical at day 20 (Fig. 5.8A). Although it was proposed that CYP7A1 and CYP8B1 were
under the same FXR regulatory pathway, CYP8B1 mRNA level was not significantly altered in
FXR-null mice (Fig. 5.8B). So the regulation of FXR on Cyp8b1 gene was relatively weak, and
there might be other regulatory factors that maintain the expression of CYP8B1 in the absence
of FXR. The expression of SHP, the direct target gene of FXR in the liver pathway for regulation
of CYP7A1 and CYP8B1, was only reduced at young ages in FXR-null mice, also suggesting
developmental stage-specific effect of FXR (Fig. 5.8C). And the result indicated that the
induction of CYP7A1 at day 60 was mainly due to failed suppression from the FXR intestinal
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Fig. 5.8

Fig. 5.8 Expression Patterns of (A) CYP7A1, (B) CYP8B1 and (C) SHP during Liver
Development.
Data are expressed as mean FPKM and SEM of three individual animals.
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pathway. Taken together, these data provided new insights for the role of FXR in regulation of
gene expression.
Phase-I Genes Potentially Targeted by FXR
Our data also suggested new Phase-I genes potentially targeted by FXR. Previous study
has shown that bile acid and FGF19 treatment decreased PON1 mRNA level (Shih et al., 2006).
And in our FXR-null mice, the PON1 mRNA level was induced during development, which
further supported the role of FXR in repression of PON1 expression, probably through intestinal
FXR function. In addition, the induction of PON2 and PON3 mRNA in FXR-null mice was also
observed (Fig. 5.9). Pon1/2/3 genes are located next to each other in the genome and it is
highly likely that they are co-regulated by FXR.
Besides Cyp7a1, only three other genes, Aldh5a1, Aldh6a1 and Dpyd, showed significant
changes of expression at all 6 ages in FXR-null mice (Fig. 5.10). ChIP-Seq study identified FXR
binding on Aldh5a1 gene (Lee et al., 2012). So the mRNA basal expression of these Phase-I
genes may be repressed by FXR. However, further study is needed to validate the direct
involvement of FXR in control of the expression of these genes.

5.5 Discussion
In this study, comparison of liver developmental transcriptome in wild-type and FXR
knockout mice by RNA-Seq revealed two major groups of findings. First, compared with wildtype mice, the deletion of FXR showed developmental stage-specific effects on different
biological processes in liver and had an overall impact to delay liver maturation at adolescent
stage. Second, the loss of FXR resulted in significant changes of Phase-I gene expression from
all 12 major families, and suggested new Phase-I genes potentially targeted by FXR.
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The effect of FXR knockout on postnatal liver development was most significant at
adolescent stage, as the pathways specifically active at neonatal stage in wild-type mice failed
to be shut down at adolescent stage in Fxr-/- mice, and the pathways that should mature before
adolescent stage remained immature in Fxr-/- mice (Fig. 5.3 and 5.4). The surge of liver bile
acids levels during this period shown by previous studies (Cui et al., 2012a) may underlie the
critical function of FXR at this developmental stage. Shown in the sample correlation heat map
(Fig. 5.2), although the similarity between neonatal and adolescent stages was higher in FXRnull mice, the correlations between day 60 sample and earlier ages were still very low, indicating
dramatic liver maturation processes happened between day 25 and day 60 in FXR-null mice. It
would be informative to study the knockout livers during this period and elucidate how the livers
overcome the loss of FXR and mature.
Our result of the multiple organ developmental processes in Fxr-/- mice further confirmed
the role of FXR as a core hepatic nuclear receptor that defines the hepatic phenotype. Six
hepatic transcription factors have been identified to form complex auto-regulatory and crossregulatory circuits (Kyrmizi et al., 2006). And the regulatory circuits may be a more pervasive
phenomenon as most of the nuclear receptors together with the core transcription factors
showed altered expressions in Fxr-/- mice (Table 5.1). While most transcriptional regulators
displayed increased expression probably to compensate FXR function, the liver X receptor α
(LXRα, Nr1h3) showed significantly decreased expression at all ages. Interestingly, LXRs and
FXR are known to be the yin and yang of cholesterol and fat metabolism, maintaining a
balanced regulation of cholesterol and bile acid metabolism (Kalaany and Mangelsdorf, 2006).
And here our results suggested a further interplay between these two nuclear receptors as FXR
may be involved in the regulation of LXRα.
Postnatal liver development is largely an under-studies area. Some groups have identified
certain critical factors for postnatal liver development, including β-Catenin and Yes-associated
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protein (Apte et al., 2007; Septer et al., 2012). These two factors showed increased expression
during postnatal liver development to promote cell proliferation, and deletion of either of them
could lead to impaired liver growth. Our transcriptome data also revealed the developmental
expression of β-Catenin and Yes-associated protein (data not shown). They were both induced
in FXR knockout mice, which is consistent with the prolonged cell proliferation in FXR knockout
livers. And the result further proved their direct roles in control of liver growth.
For the Phase-I gene expressions most altered by the loss of FXR, CYP26A1mRNA was
highly induce at day 60. CYP26A1 functions in the catabolism of retinoic acid, and is normally
induced by increased retinol or retinoic acid levels. It is possible that this gene induction is a
result of altered metabolism in retinoic acid pathway. The second gene in the distance list,
Cyp4a12, was markedly suppressed at day 60 (Fig. 5.6). Cyp4 gene family is known to be
regulated by PPAR receptors, and FXR can influence PPAR expressions. So this may also be
an indirect effect of FXR knockout. With a complicated regulatory network, it is difficult for us to
conclude on the role of FXR in some of the changes of expression patterns. ChIP-Seq
technology using specific anti-FXR antibody is a powerful tool to identify genome-wide FXR
binding sites. Future studies combining the current data with ChIP-Seq experiments during liver
development would provide important information to understand the regulatory mechanism of
FXR on Phase-I gene ontogeny.
Quantifying the developmental transcriptome is an initial step to study postnatal liver
development. It utilized advanced technology to generate an overall picture of gene expression,
and revealed potential fields of interest that await further researches. For example, histology
and liver functional studies based on the transcriptome data would help provide a more defined
concept of how the liver matures. Future studies to over-express FXR or treat the animals with
FXR agonists during development may complement the loss-of-function study and help
differentiate the direct and indirect effects of FXR in regulating postnatal liver development.
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Analyzing the role of FXR in liver maturation is critical for studying the developmental regulation
of Phase-I genes, because drug metabolism is an important liver function, and the maturation of
Phase-I enzymes is an indispensable part of live maturation. Altogether, these studies would
enable a more profound understanding of liver development and Phase-I gene ontogeny, and
provide a foundation to assist researchers in understanding developmental susceptibility and
improving the safety and effectiveness of pharmacotherapy in children.
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Fig. 5.9
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Fig. 5.9 Expression Patterns of (A) PON1, (B) PON2 and (C) PON3 during Liver
Development.
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Fig. 5.10 Expression Patterns of (A) ALDH5A1, (B) ALDH6A1 and (C) DPYD during
Liver Development.
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Chapter 6 : Conclusion and Future Directions

6.1 Conclusion
The present dissertation has systemically characterized the model of mouse liver during
postnatal development and examined the ontogenic expression signatures of all major Phase-I
drug metabolizing genes. Long non-coding RNAs and nuclear receptor FXR mediated
regulation of gene expression have been explored and addressed.
The major function of fetal liver is hematopoiesis, which is completely different from adult
liver. Dramatic changes during development are necessary for the maturation of liver functions,
and they may have significant impact on the risk of adverse drug reactions in children. Through
multi-disciplinary approaches, the present study has investigated the process of functional
transition during liver maturation. Different developmental stages revealed by transcriptome
patterns were identified, including perinatal, neonatal, adolescent and adult, which were
highlighted by changes of gene activity in various biological processes. Taking advantage of the
deep sequencing technology, the developmental expression patterns of lncRNAs were initially
characterized. LncRNAs exhibited the same major patterns as protein-coding RNAs, and
neighboring protein-coding and long non-coding RNAs showed more correlated developmental
expressions, which strongly suggested the involvement of lncRNAs in the control of liver
ontogeny.
For Phase-I metabolism, a systematic study of the ontogenic expression of 103 P450 genes
in mouse liver was performed, as well as another 11 families of Phase-I genes, including
carboxylesterase, paraoxonase, epoxide hydrolase, which function in hydrolysis; aldo-keto
reductase, quinone oxidoreductase, dihydropyrimidine dehydrogenase, which mainly catalyze
reduction

reaction;

and

alcohol

dehydrogenase,
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aldehyde

dehydrogenase,

flavin

monooxygenases, molybdenum hydroxylase, and cytochrome P450 oxidoreductase, which are
typical oxidative enzymes. Total Phase-I gene mRNA expression showed two rapidly increasing
stages after birth, reflecting the timeline for the maturation of metabolic functions. Diverse
expression patterns of Phase-I genes with enriched mRNA at different stages of development
were also identified, and the patterns were highly homologous to humans, which provide an
important foundation for further mechanistic studies.
FXR is an important nuclear receptor activated by bile acids. In the immediate perinatal
period, newborns need to synthesize and secrete bile acids into bile to facilitate the absorption
of milk. The activation of FXR around birth may be critical for hepatic gene expression at early
ages. Based on our characterized model of mouse liver development, we went on to examine
the role of FXR in regulation of liver and Phase-I gene ontogeny through comparison with age
matched FXR-null mice. The data revealed a critical role of FXR in promoting proper liver
maturation and in control of Phase-I gene expressions during development.
The details about developmental liver functional transition, showing what pathways are
matured at which stage, provide evidence to prove the general idea that pediatrics are different
from adult clinics, and give a foundation for us to understand the cause of clinical problems in
developmental pharmacology. The study on FXR has identified a novel role of FXR in liver
maturation, thus the differences in FXR activity among children can be a potential factor to help
predict possible variations and susceptibilities of pediatric patients. In conclusion, through
integrating different research models and technologies, the present dissertation has examined
the ontogenic patterns as well as possible regulatory mechanisms for phase-I drug metabolizing
gene expression during liver development, which provides novel insights into identifying and
further understanding the molecular targets for safe and efficacious drug treatments in children.
The results also build up a valuable model platform for the future study of developmental gene
expression and regulation.
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6.2 Future Directions
Factors in developmental regulation may come from endogenous, nutritional and
environmental sources. Endogenous hormones are key upstream signals in regulating gene
expression during perinatal and postnatal development. Growth hormone (GH) is a member of
an extensive GH/prolactin family of peptides. The essential role of GH in regulating body growth
and maturation of the liver is well demonstrated by the studies of lit/lit mice, which have a
spontaneous mutation in the growth hormone releasing hormone receptor (Eicher and Beamer,
1976; Noshiro and Negishi, 1986). Hepatic expression of P450s is profoundly altered in lit/lit
mice (Sharma et al., 1998; Waxman and O'Connor, 2006), demonstrating a critical role of GH in
regulating hepatic expression of these genes. It would be interesting to examine liver
developmental process in lit/lit mice to further characterize the role of growth hormone on
Phase-I gene ontogeny.
We consider the current study of FXR related to the effect of nutrition, as the natural ligand
for FXR is bile acid, the level of which can be influenced by food intake. In addition to maturation
of the bile acid processing system during postnatal liver development, weaning and food intake
will result in absorption of an increasing amount of xenobiotics. Increased absorption of
xenobiotics requires the activation of detoxification systems. PXR and CAR are classic
xenobiotic sensors in the liver, and are responsible for the inducible expression of multiple drug
processing genes. However, the role of these xenobiotic sensors in regulation of Phase-I genes
during development has not been discussed. Surprisingly, a recent study in human hepatocytes
found that altered bile acid levels could affect the basal expression of multiple P450s, probably
because bile acids are ligand activators of FXR, PXR and CAR (Chaudhry et al., 2013).
Investigating hepatic bile acid levels and the active role of PXR and CAR during development
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would be critical to understand the nutritional and environmental factors in regulation of the
maturation of drug metabolizing enzymes.
There is a group of liver enriched transcription factors that are involved in liver development,
many of which are regulated by GH, such as HNF3β, 3γ, 4α, and 6, CCAAT/enhancer binding
protein alpha (C/EBPα), C/EBPβ, c-fos and c-jun (Osafo et al., 2005). It is clear that there is
crosstalk among multiple nuclear receptors in liver. Studying the mechanism role of these
nuclear receptors in regulating gene expression may help us dissect the complex interplay
network among nuclear receptors and elucidate the overlapping and unique properties of their
functions during development.
Hepatic gene expression is hierarchically regulated by multiple mechanisms. Nuclear
receptors and other transcription factors are essential for gene regulation but lack the enzymatic
activities necessary to modulate chromatin structure. These activities are catalyzed by
coregulators recruited in response to different signals, including ligand-receptor binding
(Gronemeyer et al., 2004). Coregulators are classified as coactivators or corepressors.
Coactivators are histone acetyltransferases, methyltransferases, or their docking-partners. They
are known to interact with xenosensors like PXR (Xie et al., 2009), and involved in chromatin
relaxation and recruitment of the basic transcriptional machinery (Hankinson, 2005).
Corepressors, such as nuclear receptor co-repressor 1 (NcoR1) and silencing mediator of
retinoic acid and thyroid hormone receptors (Smrt), preferentially bind to unactivated receptors
and recruit histone deacetylases and/or demethylases, leading to chromatin condensation and
gene repression (Collingwood et al., 1999; Nishioka and Reinberg, 2001). When examining the
differentially expressed genes in FXR-null mice compared with wild-type mice during
development in our data, GO analysis identified significantly enriched biological processes of
histone modifications and chromatin remodeling. We know that the DNA sequences are
normally unaltered during development, but epigenetic signatures can be changed with the
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environment, which may play an important role in developmental regulation. Studying the
function of coregulators associated with the important hepatic nuclear receptors and the change
of epigenetic signatures in the target genes will provide more insights into the molecular
mechanism of gene regulation during development.
Studies have shown that drug treatment at early ages may lead to epigenetic memory that
affects the drug response at later ages (Chen et al., 2012). Based on our study on normal
developmental processes, future investigations about the effect of neonatal drug treatment on
variations of drug response may introduce a new concept in inter-individual variations and have
significant impact on research of personalized medicine. The successful completion of these
related studies will generate critical knowledge that will serve as the foundation for further
understanding of pediatric pharmacology in humans.
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